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1. Introduction 
1.1 Lymphomas in general 
1.1.1 Definition and classification 
The lymphomas, a diverse group of neoplastic diseases arising from the lymphoid 
system, vary from highly proliferative and rapidly fatal neoplasms to indolent 
malignancies. Scientific progress has increased our understanding of the biology of 
lymphomas and brought forth advanced technology in molecular genetics and 
immunology. During the last 30 years lymphoma classification has evolved from a 
purely morphologic and descriptive system to a complex multidisciplinary approach 
incorporating morphologic, immunophenotypic and molecular genetic features. The 
methods necessary for modern lymphoma classification may, however, not be 
available in some regions of the world, especially in the developing countries. 
The two main groups of lymphomas are Hodgkin lymphoma (HL) and non-Hodgkin 
lymphoma (NHL), each of which has various subtypes (Table 1). The majority of HL 
and NHL arise in lymph nodes (nodal lymphomas) 1, 2. Lymphomas arising from 
lymphoid cells and tissue outside lymph nodes are called extra-nodal lymphomas. 
This distinction can be ambiguous for sites such as blood, bone marrow and spleen 3 
The proportion of extra-nodal disease varies geographically with the highest reported 
incidence in developing countries 1, 4. The gastrointestinal tract represents the most 
common site of extra-nodal lymphoma whereas the second most frequent localization 
is the head and neck 4. In the latter site tonsils are most commonly affected followed 
by nasopharynx, oral cavity, salivary glands, paranasal sinuses and base of tongue 5.  
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Table 1:  Examples of lymphoma subtypes 
Lymphoma group Sub group Types (examples) 
 
 
 
 
 
 
NON-HODGKIN LYMPHOMA 
 
 
 
 
B-CELL 
B lymphoblastic lymphoma/leukaemia 
Pre-GC: Mantle cell 
GC: BL, DLBCL, Follicular 
Post GC: MZ, MALT, SLL, DLBCL, Plasma cell 
myeloma, lymphoplasmacytic 
 
T-CELL T-lymphoblastic lymphoma/leukaemia 
Peripheral T-cell, Natural killer cell 
 
 
HODGKIN LYMPHOMA Classical Nodular sclerosis, Mixed cellularity, Lymphocyte-rich, Lymphocyte-depleted 
Nodular lymphocyte predominant 
GC, germinal centre; BL, Burkitt lymphoma; DLBCL, diffuse large B-cell lymphoma; MZ, marginal 
zone; MALT, mucosa-associated lymphoid tissue; SLL, small lymphocytic lymphoma 
1.1.2 Lymphoma epidemiology 
In many parts of the world, there has been a reported increase in lymphomas 
attributed to improved cancer registration, greater awareness of the disease, changes 
in the understanding and classification of lymphoproliferative diseases, more 
sensitive diagnostic methods and the AIDS epidemic 6, 7. Particularly in the United 
States and Western Europe, an increased incidence of NHL and a decline of HL have 
been registered 8. In general, in countries where the incidence of extra-nodal 
lymphomas is high, the incidence of all other lymphomas tends to be high and the 
incidence of HL lower than that of NHL 3, 9.  
HL is relatively rare, has a higher incidence in men than in women and is more 
common in whites than in blacks in the United States 10. The age distribution of HL is 
bimodal with the first peak in the 15-34 year age-group and the second peak in 
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persons older than 55 years 11. In Africa, however, the number of children affected is 
high compared to Europe and North America 12.  
NHL is the 11th most common cancer world-wide 13. It is more frequent in males 
compared to females, and is more common in the elderly in the Western countries 14. 
Table 2 shows the prevalence of lymphomas in different regions of the world. The 
prevalence is higher in males compared to females and is higher in the more 
developed regions compared to the less developed regions. 
Table 2: NHL 5-year prevalence of lymphomas in males and females in different world regions to the 
nearest thousand; information sourced from GLOBOCAN 15. 
Region Males (Number of cases) Females (Number of cases) 
World 427000 324000 
More developed regions 254000 214000 
Less developed regions 173000 109000 
East Africa 13000 8600 
Northern Africa 6000 3500 
Southern Africa 1600 1100 
Western Africa 9300 5900 
South America 19000 14000 
North America 111000 93000 
East Asia 54000 32000 
Western Europe 45000 40000 
 
There has been reported an overall increase in incidence of NHL world-wide not 
related to age or sex 16. The incidence of NHL is highest in North America, Europe 
and central Africa, and lowest in Eastern and Southern Asia 17. The incidence is low 
in adults in Africa 12. The distribution of histologic subtypes of NHL differs across 
geographic regions 18 (Table 3). This has been attributed to differences in risk factors 
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in these regions 14. In Europe and North America, diffuse large B-cell lymphoma 
(DLBCL) and follicular lymphomas are the most common subtypes, with follicular 
lymphoma more prevalent in North America compared to Europe 18, 19. In South 
America, BL are more prevalent in the tropical parts and T-cell lymphomas are more 
frequent in the temperate areas 20, 21.  
Table 3: Prevalence of BL and DLBCL in different countries 
Country BL DLBCL  NHL cases (Total) 
Uganda 22 95 (80%) 19 (16%) 119 
Kenya 23 21 (35%) 11 (18.3%) 60 
Nigeria 24 211 (51.1%) 44 (10.7%) 413 
Croatia 25 4 (3.9%) 33 (32.5%) 120 
ILSG 19 10 (< 1%) 422 (30.6%) 1403 
USA 26 1102 24246 114,548† 
ILSG, International Lymphoma Study Group combined data from nine study sites, † Total of all 
lymphoid neoplasms 
In the Asian countries, T-cell lymphomas are more prevalent while in the Middle East 
and North Africa small intestinal lymphoma is the most common subtype 14, 27.  
In Africa, about 25000 new cases of NHL were reported in the sub-Saharan region in 
2002 and it ranked 5th in relative frequency among cancers, although the incidence 
rate is low compared to that of Europe and North America. Most NHL in Africa are 
of B-cell type and clinical series show predominance of high-grade lymphomas and a 
low prevalence of nodular neoplasms. In tropical East, Central and West Africa, 
Burkitt lymphoma (BL) accounts for between one quarter and one half of all 
paediatric cancers 12. In Uganda, reports from the Kampala cancer registry (KCR) 
indicate an annual increase in NHL of 6.7% in males and 11% in females during the 
period 1991-2006 28. BL is the third most common childhood cancer in Uganda and 
childhood BL accounts for about one third of the NHL cases 22, 29. 
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1.2 Lymphoma pathogenesis 
1.2.1 Etiological and pathogenetic factors 
Development of lymphomas is considered to be multifactorial. Several factors such as 
primary and acquired immunosuppression, infectious agents like EBV, KSHV, 
HTLV-1, HCV, HIV, H. pylori, autoimmune disorders, radiation, occupational 
exposures, lifestyle factors, diet and genetic alterations (Figure 1) are all likely to 
contribute to the development of several lymphoma subtypes. 9, 30.  
  
Figure 1: Factors related to lymphomagenesis. Modified from Goldin and Landgren 31. 
Epstein-Barr virus (EBV), a member of the herpes virus family, infects over 90% of 
the adult population. EBV has tropism for B-lymphocytes (and epithelial cells) and 
maintains latency in memory B-cells. Conditions leading to immunosuppression 
allow EBV to promote upregulated B-lymphocyte proliferation and transformation 
mediated by various proteins 32. EBV is reported to be present in nearly 100% of 
endemic BL and is associated with B-lymphoproliferative disease in the 
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immunocompromised host, DLBCL, Hodgkin lymphoma, infectious mononucleosis, 
tumors derived from T-cells and natural killer (NK) cells, nasopharyngeal carcinoma 
and stomach cancer 2, 33. The differences in prevalence, geographical and age 
distribution of the EBV-associated diseases have been attributed to social-economic 
conditions, the age at primary EBV infection, EBV strain or cellular tropism 34, 35. 
Geographical and age distribution of EBV-related HL has been reported to be similar 
to that of EBV-related BL 36. The different EBV-associated diseases may share 
expression of some latent genes as shown in Table 4. Risk factors for development of 
lymphoma may be high viral load, defective immune response or chronic infection 
with progression from a polyclonal to a monoclonal and malignant lymphoid 
response.  
Table 4: EBV latent genes expressed in EBV-associated conditions. Modified from Cohen 37 
Disease EBNA-
1 
EBNA-
2 
EBNA-
3 
LMP-
1 
LMP-
2 
EBER 
Burkitt lymphoma + - - - - + 
Nasopharyngeal carcinoma, Hodgkin lymphoma + - - + + + 
Lymphoproliferative disease, Infectious 
mononucleosis 
+ + + + + + 
Healthy carrier -/+ - - - + + 
 
NHL is a well-recognized complication of immunosuppression following organ 
transplantation, and is the second most common malignancy associated with HIV 
infection after Kaposi’s sarcoma 38. HIV-related lymphomas are categorized as those 
also occurring in immunocompetent patients, those occurring specifically in HIV-
positive patients and those occurring in other immunodeficiency states 39. Examples 
of HIV-associated lymphomas include immunoblastic, BL, CNS lymphoma, and 
body cavity based lymphomas 40. The different categories of AIDS-related 
lymphomas are related to the degree of immunodeficiency of the patient 41. Human 
herpes virus type 8 (HHV8/KSHV) which is found in nearly all Kaposi’s sarcoma 
lesions 42 is another infectious agent associated with some lymphomas. KSHV 
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seropositivity is rare in non-HIV infected patients in most American, Asian and 
European countries but is common in some Mediterranean and Central African 
countries with infection rates in Uganda of about 46% 43, 44. KSHV is associated with 
HIV-associated body cavity lymphomas and plasmablastic lymphomas 45. 
Human T-cell lymphotropic virus type 1 (HTLV-1) is endemic in Japan, the 
Caribbean, Africa, South America and is transmitted by breast-feeding, through blood 
and blood products and through sexual intercourse 30. HTLV-1 is the aetiological 
agent of adult T-cell leukaemia/lymphoma (ATLL) and the African continent 
constitutes the largest reservoir of this infectious agent. T-cell lymphomas, however, 
are rare in the most HTLV-1 endemic regions of Africa like Gabon 46, 47. 
Hepatitis C (HCV) infection is involved in a subset of NHL mainly in regions where 
high prevalence of HCV is found in the general population 48. The prevalence of 
chronic HCV infection varies in different continents with the highest prevalence in 
Africa but HCV infection among HIV-infected pregnant women in Uganda is less 
than 1% 49, 50. HCV has been found in NHL in Egypt but not in USA, further 
emphasizing the regional variation of the association of HCV with NHL 51-53.  
Among other carcinogenic agents which have been found to contribute to the 
development of lymphomas, are bacteria including H. pylori, B. burgdoriferi, C. 
trachomatis and C. Jejuni  associated with the pathogenesis of mucosa-associated 
lymphomas (MALT lymphomas) 54. There are epidemiological studies suggesting 
that exposure to herbicides and pesticides are a risk factor for the development of 
lymphoma 55.  
Immune disorders associated with lymphomas include among others; rheumatoid 
arthritis, Sjögrens syndrome, systemic lupus erythematosus, gliadin allergy, 
inflammatory bowel disorders and psoriasis 56. Somatic hypermutations, chronic B-
cell stimulation and antigenic drive as well as increased resistance to apoptosis are 
suggested as possible mechanisms in autoimmune-related lymphomagenesis 57. Many 
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B-cell NHL are derived from B-cells whose maturation in passaging through the GC 
has been blocked, disrupting the different phases of normal B-cell development 58. 
 
1.2.2 Germinal centre formation 
Germinal centres (GCs) are formed within follicles of secondary lymphoid organs as 
the main site of antigen-driven B-cell proliferation 59. When naïve B-cells encounter 
antigen, they become activated and may undergo clonal expansion and GC reaction, 
or clonal expansion and differentiation generating memory B-cells 60. Follicular 
dendritic cells (FDC) and T-cells play important roles in GC formation. Maintenance 
of the GC is associated with intact dendritic cell network and persistence of antigen 
61-63.  
Mature GCs are divided into dark and light zones. The centroblasts occupy the dark 
zone and give rise to centrocytes, while the light zone contains predominantly 
centrocytes and a rich network of follicular dendritic cells 64. Regulation of the GC 
reaction involves interaction of activation, proliferation, differentiation and death of 
B-lymphocytes 65. Germinal centre termination shows different patterns including 
progressive transformation, regression and fragmentation, each with distinct 
morphologic and immunophenotypic features although some overlapping may occur 
62. Many of the B-cells in the GC are clonally related and multiple somatic mutations 
are present in the cells. Abnormal B-cell differentiation and death in the GC, 
prolonged survival of the centrocytes coupled with hypermutation predispose to 
genetic mutations and development of a malignant phenotype 65. In the 
immunocompromised individuals, the pool of B-lymphocytes that are the target of 
translocations expands. The opportunity for spontaneous translocations are increased, 
some cells are endowed with survival advantages and lymphoma develops 66.  
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1.2.3 Relationship between the GC and lymphomagenesis 
Many B-cell NHL (Figure 2) are derived from B-cells whose maturation in passaging 
through the GC has been blocked, disrupting the different phases of normal B-cell 
development 58. This may be associated with expression of genes not normally 
expressed in a particular developmental stage of mature B-cells, resulting from 
single-base changes introduced by somatic hypermutation, class-switch 
recombinations, and VDJ recombination 67.  
 
 
Figure 2: Lymphomas with GC origin. Modified from Kuppers et al 68. 
BL is derived from early centroblasts, late GC B-cells or memory B-cells and is 
known to express GC B-cell signature genes and GC cell markers 69-72. BL has been 
reported to arise from follicular lymphoma as well as reactive lymph node 
hyperplasia 73-75. Progression from reactive lymphoid hyperplasia (follicular 
hyperplasia) to high grade lymphoma has been reported and infections like EBV may 
lead to development of lymphoma in benign lymphadenopathy 76-78. In patients with 
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lymphoid malignancies, the transformation from an indolent to a histologic pattern 
with a more aggressive course is well known 79.  
1.2.4 EBV, HIV and lymphoid proliferation 
EBV gains entry into the B-cell via interaction of the viral envelope protein 
gp350/220 with the B-cell surface molecule CD21, adsorption takes place and the 
virus is internalized 80. EBV infection of the B-cells causes them to become 
proliferating B-blasts, the blasts then enter the follicles, expand and form GCs 81. 
Latent infection is due to expression of viral proteins including Epstein-Barr virus 
nuclear antigens (EBNAs), three latent membrane proteins (LMPs) and two Epstein-
Barr virus-encoded small RNAs (EBERs) 80. These viral proteins act as oncogenes 
and have growth-promoting activity. 82.  
The HIV virus primarily infects lymphocytes, and lymph nodes are commonly 
involved during all stages of the infection. Persistent generalized lymphadenopathy 
(PGL), is a common finding in many HIV patients. Follicular hyperplasia is the most 
common finding although different architectural patterns may be seen depending on 
individual variations and disease progression 83, 84. Similar to findings concerning 
other viral infections, HIV particles have been found localized in the GC 85.  
1.3 Burkitt lymphoma 
The first case of BL in Uganda was probably reported in 1904 by Sir Albert Cook 
who described it as one of the most malignant forms of cancer 86. The first definitive 
description of what is now known as BL, was made by Dennis Burkitt in 1958, who 
also observed that although the tumors were found in different parts of the body, they 
were part of a single disease entity 87.  In 1963, it was agreed that this tumor should 
be given the name Burkitt’s tumor as a recognition of Burkitt’s work 86.   
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1.3.1 Description, epidemiology and risk factors 
There are three subtypes of BL: endemic subtype found in tropical areas (Figure 3), 
sporadic subtype in Western countries, and immunodeficiency-associated subtype 88, 
89. Some authors, however, classify BL into classical BL and atypical/Burkitt-like 
lymphoma 90. The definition of endemic BL remains controversial especially when 
defined by geography alone or if occurring in HIV high-prevalence regions 91, 92. 
Burkitt lymphoma is the third most common paediatric cancer in Uganda and 
accounts for about 90% of childhood lymphomas in Uganda 29, 93. 
 
Figure 3: Map showing the distribution of BL in the tropics. From Palmer and Reeder, The Imaging of 
Tropical Diseases 94 
The etiology of BL has been associated with EBV found in the majority of endemic 
cases, malaria, humidity, and latitude 95. Other associated etiologic agents include 
immunosuppressant therapy, exposure to the plant Euphorbia tirucalli, Chikungunya 
fever and other arbovirus infections, HIV infection and poor socioeconomic 
conditions 87, 96-98. Figure 4 shows the interaction between different factors in the 
etiology of BL. 
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Figure 4: Interaction between different factors in etiology of BL. Modified from Brady et al  99 
1.3.2 Clinical presentation and treatment 
Endemic BL typically occurs in children 2-14 years old with a male preponderance. 
Sporadic and HIV-associated BL are reported in all age groups with the adult 
sporadic cases generally being more prevalent in males compared to females 88, 98.  
Endemic BL shows a characteristic anatomical distribution (Figure 5). Oral lesions 
may present with loosening of teeth or jaw swelling while tumors originating in the 
maxilla may present as orbital tumors (Figure 6). Abdominal tumors may present as 
retroperitoneal masses, ovarian masses, liver enlargement, or gastrointestinal lesions. 
There may also be involvement of the abdominal lymph nodes, long bones, endocrine 
system, testis, salivary glands or spinal/intracranial involvement 86. Some reports 
indicate that jaw tumors predominate in endemic BL while others report that 
abdominal tumors either predominate or the percentage of jaw tumors falls after 3 
years of age 22, 86, 100, 101.  
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Figure 5: The most common sites of BL presentation are shown. They are: orbit, oral cavity, liver, 
spleen, intestines, kidneys, ovaries and testes. 
Abdominal tumors are the most common initial presentation in non-endemic BL 88. 
BL is highly responsive to chemotherapy (Figure 6) with treatment response 
dependent on disease stage, drug used and the strength of the patient’s biological 
defence against the tumor 86. Chemotherapeutic agents used include vincristine, 
cyclophosphamide, doxorubicin, methotrexate, cytarabine, cisplatin, etoposide and 
ifosfamide 102.  
In addition, monoclonal antibodies targeting specific cell surface antigens on 
malignant hematopoietic cells have also been used for treatment 103. Rituximab, an 
anti-CD20 antibody is used in conjunction with chemotherapy, and is also used for 
treatment of other B-cell lymphomas 104. The monoclonal antibodies, particularly 
rituximab may, among other mechanisms, function via induction of apoptosis or cell 
cycle arrest 105. An overall cure rate of 90% for Burkitt lymphoma and some other B-
cell lymphomas has been achieved in Europe 106. Chemoresistant or refractory disease 
is poorly understood but may be due to anti-apoptotic mechanisms in BL 
pathogenesis or complex chromosomal aberrations 107. Many children in Africa who 
develop BL, however, lack access to treatment, leading to a poor outcome  108. 
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Figure 6: This picture serves to illustrate three typical features of BL: the malignancy frequently occurs 
in children (a,c), it frequently presents as jaw (a) or orbital tumors (c) and is responsive to 
chemotherapy (b,d). The pictures are taken from a Uganda Cancer Institute calendar for the year 1976 
and had the caption ”BURKITT`S LYMPHOMA CAN BE TREATED". 
In a cohort of children with BL in Malawi, only 25% of those recruited (n= 44) 
completed therapy, 15% died and 7% of children treated were confirmed to be 
disease-free after 2 years 109. In a Ugandan BL cohort comprising of both HIV-
positive and -negative children, HIV seemed to have minimal effect on the treatment 
outcome following chemotherapy 110. Extreme poverty, difficulty to understand the 
disease process or adverse effects of treatment, the role of traditional healers, 
imprecise physical address, and inability to apply modern diagnostic techniques make 
both treatment and follow up in Africa difficult 109. 
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1.3.3 Morphology and markers 
BL is one of the most rapidly growing malignant tumors. Histologically, the typical 
endemic BL is characterized by a diffuse monomorphic infiltrate of small to medium-
sized lymphoid cells with sparse basophilic cytoplasm and round nuclei with 
dispersed chromatin and multiple medium-sized nucleoli. The proliferation rate is 
extremely high, and is reflected in many mitotic figures 107. Kinetic studies show a 
very short doubling time 111. The typical “starry sky” pattern is due to macrophages 
phagocytosing nuclear debris from apoptotic tumor cells (Figure 7) 112. This pattern, 
however,  is not pathognomonic and may be seen in other rapidly dividing tumors 
with a high cell turnover 113. Imprint preparations and examination of Romanowsky-
stained cells from centrifuged body fluids also aid in diagnosis 86,114. The majority of 
BL are negative for PAS and positive for RNA (stained with methyl green-pyronin 
Y) 86. 
 
 
 
 
 
 
Figure 7: H&E-stained slide showing the characteristic starry sky appearance of BL. Original 
magnification is 250X. 
BL express pan-B-cell and germinal centre markers 40. The typical tumor cell 
expresses surface IgM, CD19, CD20, CD22, CD79a, CD10, CD38, CD45, CD43, 
Bcl-6 but not CD5, CD23, Bcl2 or TdT 40, 89. There are, however, differences in 
expression of the different markers within and between the BL subtypes 115, 116. 
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1.3.4 Genes and molecular mechanisms in BL 
DNA mutations that alter the function of normal genes involved in cellular processes 
such as cell division, apoptosis and differentiation may lead to cancer formation 117. 
Thus, the essential hallmarks of neoplastic transformation include growth signal 
autonomy, evasion of apoptosis, evasion of growth inhibitory signals, angiogenesis, 
unlimited replicative potential and invasion and metastasis 118. Alterations in 
oncogenes, tumor suppressor genes and stability genes are the main genetic events 
leading to cancer 119. Genes that have been reported to be somatically mutated in BL 
include TP53 (p53), CDKN2A (p16), TP73 and RB2 (p130) 120.  
 
Genetics of BL 
In the majority of BL cases, there is a translocation between the MYC gene on 
chromosome 8 and the IgH gene on chromosome 14 [t(8;14)]. This translocation is 
common to both endemic and sporadic BL although differences in common site of 
involvement as well as differences in other gene mutations have been reported 121. In 
other cases, there is translocation in the kappa light chain on chromosome 2 and the 
lambda light chain (IgL) on chromosome 8 or 22 [t(2;8) or t(8;22)]. The MYC protein 
is involved in a variety of cellular processes such as cell cycle regulation, apoptosis, 
cell growth, and cell differentiation 122. Expression of MYC is positively regulated by 
factors such as BCL6, epidermal growth factor and platelet-derived growth factor, 
while it is negatively controlled by Blimp-1 or p21 123. MYC is also required for 
survival and normal differentiation of immature B-cells 122. MYC abrogates growth 
arrest caused by p27, p130 and p21 and down-regulates p15, p16 and p21 124. MYC 
gene deregulation in BL leads to high levels of MYC protein expression, removal of 
negative regulatory signals, cooperation with other genetic aberrations such as TP53 
mutations and cooperation with viral genes such as EBV genes 125. Other lymphoma-
associated translocations, such as IgH/BCL2 and translocations involving BCL6 are 
not usually detected 89.  
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Tumor suppressor genes 
Tumor suppressor genes code for proteins that play a role in inhibiting growth and 
tumor formation. They are involved in the control of normal and abnormal cell 
proliferation and their loss or inactivation is associated with development of 
malignancy. The processes of cell cycle progression and apoptosis are linked through 
tumor suppressor genes such as TP53, RB, MYC and CDKN2A 126. 
The central tumor suppressor gene TP53 encodes the p53 protein, which integrates 
signals from different pathways that become activated as a result of DNA damage or 
oncogene activation, like MYC translocation, and triggers responses that lead to cell-
cycle arrest, DNA repair, and apoptosis, among others 127. TP53 is inactivated by 
mutations in 50% of human cancers, but also through binding to viral proteins or as a 
result of alterations in genes whose products interact with p53 128. Rb/p105, p107 and 
pRb2/p130 are members of the retinoblastoma protein family and participate in cell 
proliferation and differentiation 129. pRb2 acts as a tumor suppressor in a variety of 
cell lines 130-132. Down-regulation of pRb2 is also postulated to lead to the high 
proliferation rate in high grade NHL 133. 
The cell cycle 
The cell cycle, a process that ensures that there is complete and accurate replication 
of the cell before division, is controlled by three main groups of proteins; the cyclin-
dependent kinases (CDKs), cyclins and cyclin-dependent kinase inhibitors (CDKIs) 
134. There are two known families of CDKIs, the INK4 family (p16/INK4A, 
p15/INK4B, p18/INK4C and p19/INK4D) and the CIP/KIP family consisting of p21, 
p27 and p57 135. These proteins are closely linked and play specific roles during 
specific parts of the cycle (Figure 8) after appropriate stimulation. The active cell 
cycle is divided into four phases: gap 1 (G1), synthesis (S phase), gap 2 (G2) and 
mitosis (M phase), whereas a fifth phase (G0) occurs when a viable cell is not 
involved in the active cell cycle.  
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Figure 8:  Schematic representation of the cell cycle. Adapted from Slingerland and Pagano 136        
There are checkpoints as the cell progresses from one phase of the cycle to the next 
and loss of checkpoint control may lead to genomic instability, inappropriate survival 
of the genetically damaged cells and the evolution of cells to malignancy 137. There is 
a "point of no return" during the cell cycle when the cell is committed to 
proliferation, called the "restriction point". It occurs in the G1 phase whose role is 
preventing cells from excessive cycling 138. Oncogenic processes exert their greatest 
effect by targeting particular regulators of G1 progression and genetic lesions that 
disable key regulators of G1 phase progression in mammalian cells are present in 
most human cancers 135, 139. Mutation of RB or genes affecting its function disables 
the G1 checkpoint and leads to loss of cell cycle control. Inactivation of several cell 
cycle regulators has been reported in lymphomas, and it has been postulated that the 
development of BL derives from changes that lead to cell cycle progression 120, 123. 
Translocation of MYC promotes tumorigenesis by activating CDKs and repressing 
CDKIs. 
Apoptosis 
The term apoptosis (or programmed cell death) is used to describe the situation in 
which a cell actively pursues a course toward death upon receiving certain stimuli. 
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This process plays a role in the regulation of tissue homeostasis especially in cell 
systems with a high turnover rate 140. Deregulation of apoptosis is implicated in 
pathogenesis of human neoplasms where the balance of apoptosis and proliferation is 
shifted towards proliferation either by increased mitosis and/or reduced apoptosis 141. 
Cell death by apoptosis is exerted by the coordinated action of a number of gene 
products. The relative importance of p53, MYC, Rb and apoptosis inhibitors (Bcl-2 
and its homologs) in the regulation of apoptosis in different human cancers is not 
fully understood, but p53 and Bcl-2 gene alterations have been found in many 
lymphoma subtypes 140, 142. Normal human GC cells also undergo apoptosis and 
express a number of apoptosis-inducing genes 143. Aggressive lymphomas are 
characterized by deregulation of oncogenes or tumor suppressor genes with cell cycle 
regulatory functions 123. BL as well as most non-neoplastic GC cells are usually 
negative for Bcl-2 144. The high expression of   apoptosis inhibitor proteins in NHL, 
including in BL, may indicate that resistance to apoptotic stimuli is involved in NHL 
pathogenesis 145. The proteins that function in proliferative pathways may sensitize 
cells to apoptosis and their interplay could determine cell proliferative potential 126. 
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2. Aims of the study 
The pathogenesis of lymphomas is complex, involving interactions between factors 
such as infection, immunodeficiency and genetic alterations. These factors may be 
associated with altered cytokine and oncogene expression in the tumor tissue. The 
advances in immunohistochemical and molecular genetic methods have not been 
widely applied in the African setting in general, and in Uganda in particular, to 
characterize the lymphomas and other disorders of lymphoid tissue. Employing these 
methods would improve the diagnostic quality and could provide information 
regarding the biology of lymphomas and follicular hyperplasia from Ugandan 
patients. These ancillary diagnostic methods could also be useful in documenting 
common viral infections leading to lymphoproliferative conditions in these patients.  
The main aim of the study was to examine and characterize endemic BL with special 
emphasis on the expression profile of cell cycle-associated proteins and to compare 
the findings with the situation in hyperplastic GC. We wanted to focus on the 
expression profile of the RB (pRb2/p16) and p53 (p14/p53/p21) tumor suppressor 
pathways, and to search for tumor-associated RBL2 mutations that could be involved 
in deregulated cell cycle control. We also aimed to examine a possible role of some 
recently described apoptosis-related proteins in BL. 
Additional specific aims of the study were to evaluate a possible change in the 
epidemiology of lymphomas in Uganda in the HIV/AIDS era, as reflected in the 
diagnostic profile of biopsy-verified lymphomas, and to describe the spectrum of 
reactive lymphoid hyperplasia (RLH) in Ugandan patients and their possible 
association with HIV and EBV infection 
Our study was accomplished by light-microscopic, immunohistochemical as well as 
molecular genetic investigations on archival tissue retrieved from the Department of 
Pathology, Makerere University College of Health Sciences. 
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3. Materials, methods and methodological 
considerations 
The materials and methods used are outlined in the papers included in the thesis. This 
section will summarize some aspects of the methods used and their relevance. It will 
serve to discuss the challenge of conducting retrospective studies using archival 
material in Uganda. 
This study was carried out as part of the research collaboration between the 
Pathology Department, Makerere University College of Health Sciences (formerly 
Makerere University Faculty of Medicine), Uganda and the Section for Pathology, 
The Gade Institute, University of Bergen, Norway. Basic data collection, linked to 
the histopathology report, and acquisition of paraffin-embedded biopsy blocks were 
done at Makerere University. Laboratory analysis and writing were carried out at the 
Gade Institute. 
 The Department of Pathology, Makerere University College of Health Sciences 
(MUCHS) is a research and teaching centre for both undergraduate and postgraduate 
students. The department offers a specialist course in pathology, with the main 
emphasis on histopathology. It offers diagnostic histopathology services for the main 
national referral hospital and other hospitals. The majority of Ugandan pathologists 
are based in this department, which also serves as the main national referral centre. 
Other services provided besides histopathology and teaching, include cytology and 
forensic medicine. It was the sole provider of diagnostic histopathology services for 
the entire country of Uganda up to 1990.  
The department houses the KCR, one of the oldest population-based cancer registries 
in Africa. KCR was established in 1951 with the aim of monitoring the incidence of 
cancers in the population of Kyadondo county, an area covering the capital city 
Kampala and surrounding peri-urban areas. 
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The main national referral hospital that the Department of Pathology serves has a 
capacity of 1500 beds, and is found within the same campus. The national referral 
hospital has a lymphoma treatment centre where some histologically diagnosed cases 
receive chemotherapy.  
3.1 Specimen handling 
Formalin-fixed, paraffin-embedded (FFPE) tissue blocks were retrieved from the 
archives of the Department of Pathology, MUCHS. The laboratory receives formalin-
fixed biopsies from health facilities all over the country, thus, the quality of fixation 
and handling of the specimens from the time of biopsy to the time the tissue is 
processed in the laboratory is likely to be very variable. Size and quality of the 
biopsy, specimen description, clinical information and patient data also vary 
considerably between the different health facilities.  
Preservation of tissue by fixation in formalin solution, followed by dehydration and 
paraffin wax embedding, is the main method used for preparation of histological 
sections in Uganda. The concentrations and standard of formalin used, initiation and 
duration of fixation vary. Buffered formalin is normally not employed. The 10% 
formal saline provided by the Department of Pathology is sometimes diluted further 
in the health facilities, and some health facilities use alcohol, normal saline or no 
fixatives at all. Some health facilities use the commercially available 40% formalin. 
Manual methods are used in the pathology laboratory where specimens are  processed 
by different technical staff with different levels of training. There are logistical 
problems faced within the laboratory regarding specimen handling, processing and 
storage of paraffin blocks. Open, direct flames are sometimes employed in the 
embedding processes. Haematoxylin and eosin (H&E) is the most commonly used 
staining procedure, followed by light microscopy examination of the histology 
tissues. The use of archival tissue has problems like wear and tear due to poor 
storage, improper fixation, or improper handling prior to or during embedding in 
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paraffin wax, all of which may have an effect on immunohistochemical and 
molecular genetics studies 146,147. The tissues, nevertheless, normally retain antigens 
that can be unmasked for immunohistochemical studies, and DNA/RNA can be 
extracted for genetic studies. The efficiency and yield of these methods depends on 
the quality of the material, and on factors like the heating temperature and the pH 
value of the retrieval solution used 148, 149. The blocks used in this study were re-
embedded in paraffin wax at the Department of Pathology, Haukeland University 
Hospital, Bergen, Norway and new 5-μm thick sections were made. These freshly cut 
tissue sections were re-stained with H&E, followed by a staining by the panel of 
monoclonal antibodies shown in Table 5. 
Table 5 :Antibodies used for BL immunophenotyping 
Antibody Source Antibody dilution Incubation time (minutes) 
CD45/M0701 DAKO 1:100 30 
CD20/M0755 DAKO 1:1000 30 
Bcl-6/M7211 DAKO 1:20 30 
Bcl-2/M0887 DAKO 1:100 30 
Ki-67/M7240 DAKO 1:250 30 
CD10/NCL-CD10-270 NOVOCASTRA 1:50 60 
TE9, containing 10 mM Tris, pH 9.0 and 1 mM EDTA, was used for 15 min for antigen retrieval 
3.2 Clinicopathologic information 
The clinical variables extracted from the histology request form included patient age, 
sex, site of biopsy, and HIV status (for the RLH) when available. In some of the 
cases, this information was incomplete or not available at all. Information regarding 
radiological, biochemical and hematological features associated with the tumors was 
also not specified. The lack of basic health services, imprecise demographic data and 
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poorly kept medical records all hinder accurate registration in hospital-based 
registries 150.  
Population-based cancer registries provide reliable data both in Europe and Africa 151. 
The population-based cancer registry in Uganda covers only one county in the urban 
and peri-urban areas around the capital, Kampala. Pathology data, which we used, 
have been found to include more accurate information, but may not have all the 
required details 152. The cancer registries have been reported to have  more complete 
demographic data for  adults, and higher histological confirmation for childhood 
tumors 151, 153.It was not possible, however, to retrieve and include factors like tumor 
size and clinical follow up in our study.  
3.3 Tissue microarray (TMA) 
The tissue microarray (TMA) technology is now commonly used in tumor-based 
research. The technique has been validated for immunohistochemical (IHC) analysis 
in B-cell NHL using a large panel of antibodies 22, 154. In our study, cores 1 mm in 
diameter, was taken from the BL donor blocks after having selected those with the 
typical BL immunoprofile and arranged in a new recipient paraffin block. The TMAs 
were used for all immunohistochemistry studies on BL having validated the staining 
on whole sections using the pRb2 monoclonal antibody. A major draw-back faced 
was non-informative spots caused by tissue loss due to cutting, transfer or antigen 
retrieval procedures like what has been reported by other authors 155. The use of TMA 
has the advantage that all the slides of the study are incubated in one jar, ensuring that 
concentrations, temperature of all reagents, section thickness and exposure times for 
all steps are identical for all cases 156. Other advantages include saving time and 
reagents during staining, the generation of tissue for multiple studies, and 
interpretations are based on findings within one small, highly defined area making 
their reading easier 156. 
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3.4 Immunohistochemical (IHC) methods 
Morphologic features as seen by H&E staining and light microscopy are the main 
histologic methods used in histopathology diagnosis in Uganda. Immuno-
histochemical methods, applicable in diagnosis, prognosis and monoclonal-based 
therapy in tumors 157 are not available in Uganda. In the diagnosis and classification 
of lymphomas, combining morphology and immunophenotype play a very important 
role giving most B-cell lymphomas a characteristic diagnostic profile 2. 
Formalin fixation causes inter- and intramolecular protein crosslinkages which lead to 
masking of antigens, and reduced intensity of the final reaction in the IHC procedure 
158. Unmasking of tissue antigens for demonstration by immunohistochemistry can be 
achieved by enzymatic, non-enzymatic and heat-based techniques159. The 
effectiveness of IHC staining is affected by the heating conditions, the pH and type of 
antigen retrieval solution. Thus, individual staining conditions for each antibody must 
be determined 160. Heat-induced antigen retrieval, which we used for the majority of 
antibodies, increases sensitivity and has proved useful in retrieval of antigens not 
detected when enzymatic digestion is used 160. We also employed the test battery 
approach, recommended for use on all new antibodies 161 in order to determine the 
conditions that would give optimal staining results.  
The commonly used detection methods for IHC are the avidin-biotin, streptavidin-
biotin and EnVision methods. The streptavidin-biotin method is complex, and have 
the problem of significant background staining which is increased by heat-induced 
antigen retrieval 162. We employed the EnVision method (Dako, Glostrup, Denmark), 
a two-step method that relies on a dextran backbone to which multiple enzyme 
molecules are attached. The EnVision method has been found to be faster, with less 
background staining than other methods, and can be used for detection of a spectrum 
of antigens 163-165. In addition to peroxidase for blocking endogenous enzyme activity, 
we used protein block in some instances to reduce background staining by blocking 
non-specific binding of antibody. To evaluate the staining, at least five high-power 
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fields were evaluated and combined to reach an overall percentage of tumor cell 
staining.  
In all cases, fields in different parts of the section were evaluated. Monoclonal 
antibodies against CD45 and CD20 were scored as positive or negative without any 
equivocal cases. Antibodies against Bcl-6, Bcl-2 and CD10 were judged positive 
when > 20% of tumor cells were positive, based on cut-off points suggested by other 
researchers 166, 167. Scoring of staining for the other antibodies used in the study are 
indicated in the papers included in the thesis. There is, however, no uniformly agreed 
reporting format for immunohistochemistry results in lymphomas. Different cut-off 
points and scoring methods have been used by various authors in the study of 
antibody markers in lymphomas 166, 168-170. There are now initiatives to improve the 
quality and accuracy of diagnostic slides reporting and to employ standard guidelines 
in report writing 171, 172. 
3.5 Molecular methods 
By detecting chromosomal translocations and clonal gene rearrangements, molecular 
genetic methods are now used as a supplement in the confirmatory diagnosis of 
lymphoma, and to diagnose occult disease 173. Although this is a standard practice in 
many parts in Europe, this is not the case in the majority of African countries. 
Molecular methods are also useful in studying the biology and origin of lymphomas, 
in distinguishing different subtypes and in grading 174-176. They have proven useful in 
prediction of prognosis in DLBCL 177, 178.  
Usually, FFPE tissue is the only material available for molecular analysis in a 
pathology department. The extraction from fixed tissues of DNA for genetic analysis 
by the polymerase chain reaction (PCR) is affected by the handling the specimen 
before tissue fixation, the type of fixative, fixation time, and the storage conditions 
and duration 179. There are various methods used for DNA extraction for PCR 
amplification from FFPE tissues 180. The method we employed involved placing two 
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or three 8-μm sections in 190 μl buffer G2 and 10 μl proteinase K solution of the 
MagAttract DNA mini M48 kit (Qiagen, Hilden, Germany) and dissolving by 
shaking overnight at 56°C. DNA was then purified by using the kit in combination 
with a GenoM48 BioRobot system (Qiagen) in accordance with the manufacturers 
instructions. Screening for mutations was performed by direct sequencing of exons 
amplified by PCR. FFPE tissues from Uganda have been reported to give sub-optimal 
results when used for molecular studies 181. This problem has been encountered by 
other researchers in our laboratory who observed that DNA extracted from FFPE 
tissue of Tanzanian melanoma cases resulted in less successful PCR amplification  
and mutation detection than DNA from Norwegian cases (H. Puntervoll, pers. 
communication) 182. 
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4. MAIN FINDINGS 
In Paper I, we report a decrease in histopathologically diagnosed lymphomas at the 
peak of the HIV/AIDS in Uganda (1980-1989). Burkitt lymphomas continued to be 
the most frequent subtype found. Some subtypes which are common in the 
industrialized countries were not diagnosed.  
In Paper II, we report on the association between EBV/HIV infection and reactive 
lymphoid hyperplasia (RLH). We found that RLH in Ugandan patients is frequently 
associated with EBV and HIV infection. The histologic features of the lymph nodes 
were not specific for any individual infection, but a high number of EBV-positive 
cases were associated with hyperplastic germinal centres while follicular 
fragmentation was characteristic of HIV infection. 
In Paper III, we describe the expression of pRb2 expression in endemic BL cases 
from Uganda and report our findings whether tumor-associated, somatic RBL2 
mutations could be involved in deregulated cell cycle control in these cases. We 
found that the majority of endemic BL cases from Uganda expressed pRb2 but that 
somatic RBL2 mutations had to be very rare. 
In Paper IV, we report our findings that heterogeneous RB (pRb2 or p16) and p53 
(p53, p14, or p21) pathway alterations occur frequently in BL. We found close 
similarities between BL and RLH in expression of the cell cycle regulator proteins 
examined, except for a much higher and frequent expression of p53 in BL. 
In Paper V, we report the expression pattern of apoptosis-related proteins TSP-1, 
survivin and livin in BL, compared to the findings in reactive follicular hyperplasia in 
Ugandan patients. We found strong expression of these proteins, both in BL and 
RLH. No statistically significant association between the proteins in either BL or 
RLH could be proven. 
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5. DISCUSSION 
5.1 METHODOLOGICAL CONSIDERATIONS  
Patient records 
In Paper I, we used data obtained from the patient records for the years 1980-1989, 
stored in the files of the Department of Pathology, MUCHS. The data were available 
in the department archives as recorded on the histology report forms. The quality of 
this data depends on the accuracy of information given by the patients, the clinician, 
the pathologist, and the person recording the information. It follows that the 
registration may suffer from mistakes, shortages and inconsistencies. Nevertheless, 
data from histopathology forms  have been the basis for studies by other scholars, 183 
and the ones we used are much the same as those accumulated by the Kampala 
Cancer Registry (KCR), a population-based cancer registry in Kampala, Uganda 153.  
Histopathology laboratory records are useful in providing epidemiological 
information, but it is advised that such a laboratory should serve a defined hospital or 
geographical location 184. Our clinical data are, however, neither from a single 
hospital nor from a single defined geographical location. There are, however,  reports 
of agreement between the histopathology laboratory-based data and the incidence of 
cancer in the population, even when the laboratory data were not from a defined 
population base 184. Hospital-based cancer registries have the pitfall of registering 
only those patients who are admitted to hospital, leading to underreporting 150. Other 
problems we encountered included lack of a standardized lymphoma classification, 
miscoding, and coding of similar diagnostic entities in different ways. Despite these 
limitations, we concluded that the information obtained was sufficient for the purpose 
of our study and comparable to what is accepted for KCR-based epidemiologic 
studies153. Knowledge of cancer trends in Africa is reported to be low because of the 
large burden of communicable diseases and is mainly based on case series 185.  
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We compared the frequency of some major lymphoma subtypes in two periods. The 
lymphoma classification systems have evolved and been modified over time186. These 
changes have not been adopted yet by some histopathology laboratories. The 
procedure of analysing histological specimens is much the same today in Uganda as 
was the case in the 1960ies and 1980ies. Different and inconsistent terminology, 
however, has been used.  In order to attain a relatively uniform classification, a 
lymphoma “translation system” that integrates different concepts and entities has 
been described 187.  Where necessary and possible we used this translation system.  
An alternative to the employed method would have been complete microscopic 
review of the biopsies included in our series. This was attempted, but the slides and 
even many paraffin blocks were of very low quality because of the standard of 
fixation, preparation and storage and had undergone extensive deterioration. We, 
however, retrieved and re-embedded a selected number of BL and RLH cases of a 
quality sufficient for a reliable diagnosis. This yielded the material that was included 
in our immunohistochemical and molecular studies.  
Clinicopathological variables 
We obtained the clinicopathological variables by reviewing the information on the 
histology forms in the archives of the Department of Pathology, MUCHS. As stated 
above, the accuracy of this information depends on the information provider as well 
as the person recording it. In many instances, even information about age and gender 
was lacking. Clinical and follow-up information on site of disease and stage at 
diagnosis was also not readily available. It was therefore not possible for us to 
determine the prognostic significance of the markers we investigated. Cancer 
registries are reported to continue updating their registries even after initial diagnosis 
for completeness of the information 153, but this is not feasible at MUCHS. Biopsies 
are received from all over the country, and some investigations required for staging 
are not available at a number of hospitals or, where available, the patient has to meet 
the costs. This may also affect availability of detailed clinical parameters. 
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Use of archival tissue 
We compiled typical BL and RLH cases from the files of the Department of 
Pathology at MUCHS where the surgical biopsy specimens as are stored as FFPE 
blocks. This provides a large tissue biobank. As the blocks are collected and stored at 
the time of surgical pathology diagnosis, they may not undergo the rigorous and 
careful procedures that would be applied to research material. The archival material 
may have patient information stored as well and in good settings may be used for 
follow-up studies of patients. Although surgical pathology specimen archives are 
valuable resources, little is usually done in Africa to optimize specimen storage 
conditions, quality assurance or quality control 188. Formalin fixation does not 
necessarily destroy the antigens and it is possible to use a number of antigen retrieval 
methods to perform immunohistochemistry on FFPE  tissues 159. The variations in 
methods and quality of tissue fixation, processing and storage conditions may, 
however, reduce both antigen immunoreactivity and influence the result of molecular 
pathologic studies. 
Tissue microarray (TMA) 
The technique has been validated for immunohistochemical (IHC) analysis in B-cell 
NHL using a large panel of antibodies 22, 154. The most important step in TMA 
construction is the collection of suitable samples. It is recommended that the 
diagnosis should be revised, fresh sections cut and stained by H&E, and the area of 
interest selected 155. We initially revised the diagnosis using whole sections and a 
panel of antibodies. The blocks fulfilling the criteria for diagnosis of BL were then 
selected for TMA. After practicing, precision and accuracy were achieved and we 
used this technique to assemble the 51 BL cases. The slides were then stained with 
H&E and with the same panel of antibodies that had been used on the whole sections 
for confirmation of the diagnosis. This showed that the TMA method used was 
representative.  
When staining the TMA with additional antibodies, whole sections were cut 
separately from ten of the cases included in the TMA block, and they were treated 
  40
and evaluated in the same way as the TMA slides. The use of TMA in studies of 
NHL is, as we also observed in the present work, advantageous because there are 
almost no cores without tumor cells. These arrays are also reported to be cost-
effective in terms of reagents and materials, time for performing the 
immunohistochemistry and interpretation of the slides 189. The TMA procedure is 
time-consuming as far as selection of representative donor blocks and cores is 
concerned. The major drawback that we faced, however, was loss of cores. 
Immunohistochemical methods 
Immunohistochemistry is widely used to study expression of specific proteins in 
human malignancies. In the lymphoid neoplasms, immunohistochemical expression 
of certain markers is among the criteria for classification 2. The factors that have an 
impact on the validity of immunohistochemistry include tissue fixation and 
processing, unmasking of epitopes, sensitivity of the detection system and antibody 
quality 146. Antigen retrieval is therefore important in order to achieve accurate and 
consistent results. A number of antigen retrieval methods including enzymatic and 
non-enzymatic methods have been described, but heat is reported to be the most 
important factor in unmasking antigens 159. Different unmasking solutions are also 
available to achieve optimal results. The manufacturers of the various antibodies 
issue guidelines for suggested retrieval methods although the actual practice may 
vary from the guidelines. We also employed a test battery approach, recommended 
for use on all new antibodies 161, in order to determine the conditions that would give 
optimal staining results. These included testing of different retrieval buffers, with 
different enzymatic methods or boiling schemes, different antibody dilutions and 
different incubation periods. In the case of the p16 antibody, we did not need to use 
any antigen retrieval method. 
Antigen retrieval of the archival tissue presented one of the biggest challenges of this 
study. There is a marked variation in the concentration of formalin used and in the 
fixation times of the specimens received at the pathology laboratory at MUCHS. 
Prolonged fixation seemed to be common for samples submitted from up-country 
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centres since a certain number of specimens have to accumulate before they are 
transported to the laboratory. Another issue regarding fixation is the unclear 
concentration of the formalin used. Whereas neutral, buffered formalin is not 
available, 40% formalin is sometimes used. At other times the pre-prepared 10% 
formalin solution is further diluted. Moreover, embedding of the tissue into paraffin 
blocks was until recently done using an open flame. This is expected to have an 
impact on the antigenicity of the fixated proteins. The tissue storage conditions are 
also not optimum, with the blocks being stored in warm, dusty rooms. These factors 
might have contributed to the difficulty that we encountered in antigen retrieval. This 
challenge was met by determining the appropriate antigen retrieval times for each 
antibody under consideration as described above, and also by re-embedding the 
specimens at the Department of Pathology, University of Bergen. 
The choice of antibodies used for confirming the diagnosis of BL was based on the 
WHO classification of lymphomas 25. The selection of antibody clones for the other 
markers was guided by accessible literature and relevance for the aims of the study. 
We then modified our protocols to adjust for differences in immunoreactivity due to 
the differences in quality of tissues and antigenicity. We applied a system for staining 
evaluation used by others in order to be able to compare results and because there is 
no generally accepted uniform method for reporting immunohistochemical staining 
that can be applied to most markers. Appropriate positive controls were selected from 
sections made from specimens known to express the antigen of interest, the most 
commonly used tissue being tonsils. The negative control technique used was 
omitting the primary antibody and otherwise staining as for the positive controls. This 
was done during all the rounds of staining. 
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Molecular methods 
Formalin-fixed, paraffin-embedded tissue may be the only material available for 
molecular analysis in a pathology department. Archival FFPE human tissue 
collections are, however, reported to be in poor states of storage across the 
developing world, making nucleic acid extraction from these tissues difficult. The 
fixation of tissues in formaldehyde leads to cross-linking of tissue components, and 
fragmentation or destruction of nucleic acids 190. As discussed above, successful PCR 
amplification of DNA from FFPE tissue may be difficult and is dependent on a 
variety of factors 191 which may lead to poor quality of the extracted DNA. It is 
therefore not strange that we found it challenging to perform the molecular studies, a 
problem previously encountered by other researches using FFPE tissues from Africa 
181, 182. This problem occurred despite using a kit that has been recommended as well-
suited for isolating DNA from FFPE specimens 191. The differences in conditions of 
fixation (time, temperature and fixative) as a barrier to extraction of quality DNA 
have been noted by others as well 190. Also a group from Uganda has reported 
difficulty in recovering DNA from FFPE tissue despite using different methods. 
However, it was noted that detectable DNA after extraction always lead to successful 
amplification 192. 
5.2 DISCUSSION OF MAIN FINDINGS 
The lymphomas, a diverse group of neoplastic diseases arising from the lymphoid 
system, vary from highly proliferative and rapidly fatal neoplasms to indolent 
malignancies. NHL is the 10th most common cancer in the developing word, its high 
incidence in sub-Saharan African countries being attributed mainly to Burkitt 
lymphoma 193. The incidence of cancer is expected to increase in the developing 
countries in the years to come 150. Moreover, the current cancer incidence is most 
likely under-estimated in Africa. NHL are reported to be among the most common 
malignant tumors in Africa, but are more frequent in developed compared to 
developing countries 16, 185, 194. NHL was reported to be on the increase in the United 
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States between 1973 and 1989 1. The risk of developing lymphomas, especially NHL 
has been found to be much higher among HIV patients compared to people without 
HIV/AIDS 195. One aim of our study was to investigate the prevalence and patterns of 
lymphoma in the HIV/AIDS pandemic in Uganda (PAPER I) when a rise in the 
frequency of lymphomas could be expected. However, we found that there was a 
decrease in histopathologically diagnosed lymphomas at the peak of the HIV/AIDS 
epidemic in the Uganda.  
This is in contrast to HIV-associated Kaposi’s sarcoma which is reported to have 
increased significantly among Ugandan patients. The low prevalence of some cancers 
among HIV/AIDS patients has been attributed to low patient survival 29 which may 
show geographical differences and be related to the risk of intercurrent infectious 
diseases, the standards of health care and possibilities for treatment. Another 
explanation of our findings is underreporting due to shortage of resources available 
for diagnostic services and shortage of laboratory specialists in developing countries, 
Uganda inclusive 196.  Health care spending is also still low in sub-Saharan Africa and 
families rely on informal arrangements for health care. This may lead to the 
unfortunate situation that many patients, cancer patients inclusive, do not seek formal 
health care. NHL were the most frequent with BL the most common subtype in our 
series, similar to findings by other researchers 12,  93. Very few HIV-infected patients 
in Uganda are on anti-retroviral therapy 197, 198,and immunosuppression due to HIV 
infection may account for the low number of HL. Our findings are in agreement with 
the findings of others who have reported a decrease in HL cases among Ugandan 
patients 29  
The classification of NHL has been an area of controversy. The use of widely 
different classifications has caused inconsistency and confusion. In the recent WHO 
classification of lymphomas, it is required that immunohistochemistry is applied, but 
this is not yet possible in our laboratory in Makerere. This is also the situation in 
other regions of Africa 23, 183 and is mainly attributed to the lack of resources. Some 
types of NHL, including body cavity-based lymphoma and primary brain lymphoma, 
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may be considered to be AIDS-defining when observed in a patient 41. However, we 
did not find reports of either these types or of T-cell lymphomas in our study. This 
again could be attributed at least partly to limitations in the diagnostic facilities 
available. 
Lymphadenopathy is a common clinical finding in Africa, which may occur in any 
age group in symptomatic or asymptomatic patients. Infection, autoimmune 
disorders, benign and malignant lymphoproliferative disorders among others, are the 
common causes of lymphadenopathy 199. The most common infections causing 
lymphadenopathy are tuberculosis (TB), HIV, EBV, and toxoplasmosis 200. EBV is 
associated with infectious mononucleosis and subtypes of both NHL and HL. HIV is 
associated with benign lymphadenopathy, including RLH, in addition to 
malignancies like NHL and Kaposi’s sarcoma (KS). Lymphadenopathy has been 
reported to be a common finding in HIV-infected children in Uganda, and   TB and 
KS  are frequently contributing to  the lymphadenopathy 201. A large proportion of the 
biopsied enlarged lymph nodes is, however, diagnosed as reactive lymphoid 
hyperplasia (RLH) not indicative of a specific etiologic agent 202. 
51.2% of the lymph node biopsies examined in 2005 at the Department of Pathology, 
MUCHS, were diagnosed as RLH, a finding comparable to what has been reported 
elsewhere 203. The microscopic examination was done, however, without the 
application of ancillary techniques like immunohistochemistry. In agreement with 
previous reports 204, we found a predominance of follicular type of RLH (PAPER II). 
Similar to other studies 203, 204, a specific diagnosis could not be made in some of the 
lymph node biopsies. This may be attributed to our use of a limited panel of 
antibodies and ancillary techniques in trying to identify the causes. Some causes of 
lymphadenopathy are also difficult to diagnose when there is limited or no clinical 
information provided to the pathologist. However, even in cases where extensive 
investigations are done, it may still not be possible to prove a causative agent 202. 
Specific common causes of lymphadenopathy like TB were not included in our 
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series. We only included the lymph nodes diagnosed as reactive lymphadenitis or 
non-specific lymphadenitis.  
Similar to others 205, 206, we found EBV and HIV positivity as probable important 
causes of lymphadenopathy. Some of our cases had been serologically diagnosed 
with HIV, but a clinical diagnosis of EBV was not indicated in any of the patients. 
Although seropositivity for EBV is high in the Ugandan population 207, a clinical or 
histologic diagnosis of EBV-associated lymphadenopathy is not commonly made. 
Dose of the virus in addition to other factors may also play a role in the development 
and manifestation of clinical disease 208. A high number of cases are most likely 
subclinical without obvious signs of infection and there is often lack of access to 
affordable reliable diagnostic tests 209. Similar to other authors 210, we found 
concurrent EBV and HIV infection in 46 (52.2%) of the reactive lymph nodes. 
Lymphadenopathy, a common finding in HIV patients, presents with varied 
morphological picture but the most common finding is reported to be florid follicular 
hyperplasia 85, as was the case in our series (PAPER II). 
EBV has been associated with the etiology of a number of diseases, Burkitt 
lymphoma inclusive. It is therefore not surprising that we found expression of EBV 
proteins in a majority of our BL cases (PAPER IV). Lymphomas are believed to 
arise from certain stages of normal lymphocyte development with oncogenic 
alterations or loss of responsiveness to external stimuli 60.  
Altered expression of the proteins involved in the cell cycle pathway has been 
associated with the pathogenesis of BL 123. However, contrary to findings reported by 
other authors, 211 we could not reveal any RBL2 mutations in the tissues examined 
(PAPER III). RBL2 mutations have, however, not been detected in sporadic BL by 
other researchers 212. Although previous reports have suggested a reduction in 
expression of pRb2 with increasing grade of malignancy, 213, 214 we found a high 
expression level of pRb2 in both BL and RLH (PAPER III). Similar to others, 215 we 
also found that pRb2 expression was nuclear in the majority of cases. The function of 
pRb2 is reported to depend on correct subcellular localization 216. In addition to other 
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mechanisms, viral protein binding 217 may be responsible for the high levels of pRb2 
expression. The majority of our BL cases were positive for EBV (PAPER IV).  
Altered expression of proteins regulating the retinoblastoma (RB-cyclin D1/cdk4/6-
p16) and the p53 (p53-p21/WAF1-p14/ARF) pathways are implicated in malignant 
transformation 218. We found a high frequency of Rb and p53 pathway alterations in 
BL (PAPER IV). This is in agreement with others who have found these pathway 
alterations in lymphoid neoplasms 219-222. These alterations have been reported to 
have prognostic implications 220, 221, 223. Unfortunately, we could not investigate this 
in our studies because follow-up patient data were not available.  
In accordance with BL being GC-derived, BL and RLH showed close similarities in 
the expression profile of the major cell cycle regulator proteins examined. Our 
findings, however, indicate that there is a major shift in the cycle from reactive to 
neoplastic state linked to the p53 protein. The pattern of p53 and p21 
immunoreactivity is also reported to predict p53 mutation status, where p53 
overexpression and p21 under expression is indicative of a p53 mutation 224. This 
would indicate that the proportion of BL in our series with p53 mutations is not very 
different from that without mutations. This contradicts previous reports that p53 
mutations are very common in BL 225.  Also contrary to previous studies 220, we 
found that BL and RLH are heterogeneous in the expression of the proteins belonging 
to the Rb and p53 pathways. We also included a higher number of BL specimens than 
used in the previous studies. The majority of our cases were also positive for EBV, 
whose role can not be neglected. Notably, there are no reported significant 
differences in p53 mutations in EBV-positive versus EBV-negative BL cases 226.  
Deregulation of apoptosis is implicated in pathogenesis of human neoplasms where 
the balance of apoptosis and proliferation is shifted towards proliferation either by 
increased mitosis and/or reduced apoptosis 141. Deregulated apoptosis has been 
reported in a number of lymphoproliferative disorders, and reported to be of 
prognostic significance 140. Reduced apoptosis increases cell survival, and is achieved 
through the family of apoptosis inhibitor proteins.  We found a high rate of 
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expression and close similarities in the expression profile of the inhibitor proteins 
examined in both BL and RLH (PAPER V) despite the high rate of apoptosis in both.   
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6. CONCLUSIONS AND FUTURE PERSPECTIVES 
In this thesis, we have examined the diagnostic profile of lymphomas in Uganda in 
the HIV/AIDS era, and studied the expression profile of some cell cycle- and 
apoptosis-associated proteins in BL and RLH. The following conclusions may be 
drawn: 
 
1. There has been a decrease in histopathologically diagnosed lymphomas in 
Uganda in the period 1980-1989. Burkitt lymphoma continued to be the most 
common subtype. Some subtypes, like follicular lymphomas, T-cell 
lymphomas and body cavity based lymphomas, were not reported at the peak 
of the HIV/AIDS era (PAPER I). 
2. RLH in Ugandan patients was frequently associated with EBV and HIV 
infection. The histologic features of the lymph nodes were not specific for any 
individual infection. A high number of EBV-positive cases were associated 
with hyperplastic germinal centres. Follicular fragmentation was characteristic 
of HIV infection (PAPER II). 
3. The majority of endemic BL from Uganda expressed pRb2, but somatic RBL2 
mutations affecting the protein’s nuclear localization signal appeared to be 
very rare (PAPER III). 
4. Heterogeneous RB (pRb2 or p16) and p53 (p53, p14, or p16) pathway 
alterations occurred frequently in BL. Close similarities were found between 
BL and RLH. A major difference, however, was found in the expression of 
p53, which was significantly more frequent in BL. (PAPER IV). 
5. There was a strong expression of the apoptosis inhibitor proteins SURVIVIN 
and LIVIN and the pro-apoptotic protein TSP-1 in BL and RLH. (PAPER V). 
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Several forms of BL have been described. Some variants are difficult to discriminate 
from other subtypes of high-grade NHL 227. Endemic BL is the most common 
subtype in Africa 98. Its clinical and morphologic characteristics have made the 
diagnosis of this variant of BL rather straightforward and consistent.  
We observed that BL is still the most common subtype of NHL diagnosed in Uganda. 
The tumor continues to occur in the young age group as was first described by 
Dennis Burkitt more than 50 years ago 86. Surprisingly the incidence of biopsy-
verified BL has not increased in Uganda during the HIV era. It would be of interest to 
reveal the reason why.  Is it just a matter of underreporting or are there biological 
reasons for our findings? Similarly, there is also a need to explore further why some 
lymphoma subtypes, especially T-cell lymphomas, CNS lymphomas and the HIV-
associated body cavity lymphomas, are not reported in the Ugandan population. 
In western countries, follicular lymphoma is the most common NHL subtype. This is 
in sharp contrast to our findings in Uganda. The low frequency found can hardly be 
explained by the lack of ancillary diagnostic methods as most follicular lymphomas 
are easily diagnosed by conventional light microscopy if the biopsy material is 
adequate. One reason for the difference found may therefore be underreporting. 
Another possibility is the difference in life expectancy. Follicular lymphomas occur 
predominantly in adults after the age of 40, and are seen only occasionally in 
children. 
We also found that a large fraction of reactive lymphadenopathy in Ugandan patients 
is associated with EBV and HIV infection, both of which have been implicated in the 
causation of BL 89. Because HIV prevalence in Uganda is still high, and 
lymphadenopathy is a common finding even where HIV/AIDS is not clinically 
suspected, we recommend that pathologists should be particularly aware of HIV-
associated lymphadenopathy in their practice. 
Except for the high frequency of p53 positivity found in BL, we could not find any 
statistically significant difference between BL and RLH in the expression profile of 
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most of the cell cycle- and apoptosis-associated proteins examined. However, the 
expression profile of the proteins varied. Thus, our findings open up for future 
projects to examine whether this divergence has prognostic impact in BL similarly to 
what has been reported for other subtypes of NHL 221. Extended studies are also 
needed to determine whether there is an association between the protein expression 
profile and the different variants of BL (endemic, sporadic, HIV-associated) or BL-
related patient characteristics (age, gender, site of tumor, stage, survival etc.) 
Progress in clinical management of lymphomas have demanded increasingly precise 
lymphoma classification and subtyping. In Uganda lymphoma diagnosis is still based 
solely on morphology. There is a strong demand for competence building in 
hematopathology. The procedures and methods concerning specimen handling, 
fixation, processing and storing have to be improved, and immunohistochemical and 
molecular genetic techniques need to be implemented. Moreover, the clinicians 
should be encouraged to provide complete patient information as this could be of 
vital importance for both a proper diagnosis, adequate treatment of the patient and 
clinicopathological studies. 
The incidence of BL is high in Uganda compared to other countries. This offers great 
opportunities for both clinicians and pathologists to gain extraordinary high 
competence in this field of pathology and oncology. Further studies and competence 
building may lead to advances in diagnostics and therapy, improving the quality of 
life and prognosis for the individual patient. 
 
 
 
 
  51
7. REFERENCES 
 
1. Weisenburger, D.D. Epidemiology of non-Hodgkin's lymphoma: recent findings 
regarding an emerging epidemic. Ann Oncol. 1994;5 Suppl 1:19-24. 
2. Swerdlow, H.S., Campo, E., Harris, N.L., Jaffer, E.S., Pileri, A.S., Stein,  H., Thiele, 
J., Vardiman, J.W. WHO Classification of Tumours of Haematopoietic and Lymphoid 
tissues., (IARC Press, Lyon, 2008). 
3. Newton, R., Ferlay, J., Beral, V. & Devesa, S.S. The epidemiology of non-Hodgkin's 
lymphoma: comparison of nodal and extra-nodal sites. Int J Cancer. 1997;72:923-
930. 
4. Zucca, E., Roggero, E., Bertoni, F. & Cavalli, F. Primary extranodal non-Hodgkin's 
lymphomas. Part 1: Gastrointestinal, cutaneous and genitourinary lymphomas. Ann 
Oncol. 1997;8:727-737. 
5. Zucca, E., Roggero, E., Bertoni, F., Conconi, A. & Cavalli, F. Primary extranodal 
non-Hodgkin's lymphomas. Part 2: Head and neck, central nervous system and other 
less common sites. Ann Oncol. 1999;10:1023-1033. 
6. Hartge, P. & Devesa, S.S. Quantification of the impact of known risk factors on time 
trends in non-Hodgkin's lymphoma incidence. Cancer research. 1992;52:5566s-
5569s. 
7. Bray, I., Brennan, P. & Boffetta, P. Recent trends and future projections of lymphoid 
neoplasms--a Bayesian age-period-cohort analysis. Cancer Causes Control. 
2001;12:813-820. 
8. Adamson, P., et al. Time trends in the registration of Hodgkin and non-Hodgkin 
lymphomas in Europe. Eur J Cancer. 2007;43:391-401. 
9. Baris, D. & Zahm, S.H. Epidemiology of lymphomas. Curr Opin Oncol. 
2000;12:383-394. 
10. Grufferman, S. & Delzell, E. Epidemiology of Hodgkin's disease. Epidemiol Rev. 
1984;6:76-106. 
11. Medeiros, L.J. & Greiner, T.C. Hodgkin's disease. Cancer. 1995;75:357-369. 
12. Cancer in Africa Epidemilogy and Prevention.  Lyon: IARC Press; 2003 [updated 
2003; cited 16th February 2009]; Available from: 
http://www.iarc.fr/en/Publications/PDFs-online/Cancer-Epidemiology/IARC-
Scientific-Publication-No.-153. 
13. Parkin, D.M., Pisani, P. & Ferlay, J. Estimates of the worldwide incidence of 25 
major cancers in 1990. Int J Cancer. 1999;80:827-841. 
14. Muller, A.M., Ihorst, G., Mertelsmann, R. & Engelhardt, M. Epidemiology of non-
Hodgkin's lymphoma (NHL): trends, geographic distribution, and etiology. Ann 
Hematol. 2005;84:1-12. 
15. IARC. GLOBOCAN 2002 database.  (2002). 
16. Fisher, S.G. & Fisher, R.I. The epidemiology of non-Hodgkin's lymphoma. 
Oncogene. 2004;23:6524-6534. 
17. Parkin, D.M. The global burden of cancer. Semin Cancer Biol. 1998;8:219-235. 
18. Anderson, J.R., Armitage, J.O. & Weisenburger, D.D. Epidemiology of the non-
Hodgkin's lymphomas: distributions of the major subtypes differ by geographic 
locations. Non-Hodgkin's Lymphoma Classification Project. Ann Oncol. 1998;9:717-
720. 
  52
19. A clinical evaluation of the International Lymphoma Study Group classification of 
non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. 
Blood. 1997;89:3909-3918. 
20. Sandlund, J.T., et al. Predominance and characteristics of Burkitt lymphoma among 
children with non-Hodgkin lymphoma in northeastern Brazil. Leukemia. 
1997;11:743-746. 
21. Aozasa, K., Takakuwa, T., Hongyo, T. & Yang, W.I. Nasal NK/T-cell lymphoma: 
epidemiology and pathogenesis. Int J Hematol. 2008;87:110-117. 
22. Tumwine, L.K., et al. B-cell non-Hodgkin lymphomas in Uganda: an 
immunohistochemical appraisal on tissue microarray. Hum Pathol. 2008;39:817-823. 
23. Cool, C.D. & Bitter, M.A. The malignant lymphomas of Kenya: morphology, 
immunophenotype, and frequency of Epstein-Barr virus in 73 cases. Hum Pathol. 
1997;28:1026-1033. 
24. Okpala, I.E., Akang, E.E. & Okpala, U.J. Lymphomas in University College 
Hospital, Ibadan, Nigeria. Cancer. 1991;68:1356-1360. 
25. Jakic-Razumovic, J. & Aurer, I. The World Health Organization classification of 
lymphomas. Croat Med J. 2002;43:527-534. 
26. Morton, L.M., et al. Lymphoma incidence patterns by WHO subtype in the United 
States, 1992-2001. Blood. 2006;107:265-276. 
27. Cooper, B.T. & Read, A.E. Small intestinal lymphoma. World J Surg. 1985;9:930-
937. 
28. Parkin, D.M., Nambooze, S., Wabwire-Mangen, F. & Wabinga, H.R. Changing 
cancer incidence in Kampala, Uganda, 1991-2006. Int J Cancer.126:1187-1195. 
29. Wabinga, H.R., Parkin, D.M., Wabwire-Mangen, F. & Nambooze, S. Trends in 
cancer incidence in Kyadondo County, Uganda, 1960-1997. Br J Cancer. 
2000;82:1585-1592. 
30. Franchini, G., Ambinder, R.F. & Barry, M. Viral Disease in Hematology. 
Hematology Am Soc Hematol Educ Program. 2000:409-423. 
31. Goldin, L.R. & Landgren, O. Autoimmunity and lymphomagenesis. Int J Cancer. 
2009;124:1497-1502. 
32. Bishop, G.A. & Busch, L.K. Molecular mechanisms of B-lymphocyte transformation 
by Epstein-Barr virus. Microbes Infect. 2002;4:853-857. 
33. Delecluse, H.J., Feederle, R., O'Sullivan, B. & Taniere, P. Epstein Barr virus-
associated tumours: an update for the attention of the working pathologist. J Clin 
Pathol. 2007;60:1358-1364. 
34. Henle, W. & Henle, G. Epidemiologic aspects of Epstein-Barr virus (EBV)-
associated diseases. Ann N Y Acad Sci. 1980;354:326-331. 
35. Abdel-Hamid, M., Chen, J.J., Constantine, N., Massoud, M. & Raab-Traub, N. EBV 
strain variation: geographical distribution and relation to disease state. Virology. 
1992;190:168-175. 
36. Weinreb, M., et al. The role of Epstein-Barr virus in Hodgkin's disease from different 
geographical areas. Arch Dis Child. 1996;74:27-31. 
37. Cohen, J.I. Epstein-Barr virus infection. N Engl J Med. 2000;343:481-492. 
38. Franceschi, S., Dal Maso, L. & La Vecchia, C. Advances in the epidemiology of 
HIV-associated non-Hodgkin's lymphoma and other lymphoid neoplasms. Int J 
Cancer. 1999;83:481-485. 
39. Carbone, A. & Gloghini, A. AIDS-related lymphomas: from pathogenesis to 
pathology. Br J Haematol. 2005;130:662-670. 
40. Knowles, D.M. (ed.) Neoplastic Hematopathology, (Lippincott Williams and 
Wilkins, Baltimore, 2000). 
  53
41. Carbone, A. Emerging pathways in the development of AIDS-related lymphomas. 
Lancet Oncol. 2003;4:22-29. 
42. Schalling, M., Ekman, M., Kaaya, E.E., Linde, A. & Biberfeld, P. A role for a new 
herpes virus (KSHV) in different forms of Kaposi's sarcoma. Nat Med. 1995;1:707-
708. 
43. Hayward, G.S. KSHV strains: the origins and global spread of the virus. Semin 
Cancer Biol. 1999;9:187-199. 
44. Serraino, D., et al. A seroprevalence study of human herpesvirus type 8 (HHV8) in 
eastern and Central Africa and in the Mediterranean area. Eur J Epidemiol. 
2001;17:871-876. 
45. Carbone, A., Cesarman, E., Spina, M., Gloghini, A. & Schulz, T.F. HIV-associated 
lymphomas and gamma-herpesviruses. Blood. 2009;113:1213-1224. 
46. Hunsmann, G., et al. Antibodies to ATLV/HTLV-1 in Africa. Med Microbiol 
Immunol. 1984;173:167-170. 
47. Walter, P.R., Klotz, F., Alfy-Gattas, T., Minko-Mi-Etoua, D. & Nguembi-Mbina, C. 
Malignant lymphomas in Gabon (equatorial Africa): a morphologic study of 72 
cases. Hum Pathol. 1991;22:1040-1043. 
48. Negri, E., Little, D., Boiocchi, M., La Vecchia, C. & Franceschi, S. B-cell non-
Hodgkin's lymphoma and hepatitis C virus infection: a systematic review. Int J 
Cancer. 2004;111:1-8. 
49. Madhava, V., Burgess, C. & Drucker, E. Epidemiology of chronic hepatitis C virus 
infection in sub-Saharan Africa. Lancet Infect Dis. 2002;2:293-302. 
50. Pirillo, M.F., et al. Seroprevalence of hepatitis B and C viruses among HIV-infected 
pregnant women in Uganda and Rwanda. J Med Virol. 2007;79:1797-1801. 
51. King, P.D., Wilkes, J.D. & Diaz-Arias, A.A. Hepatitis C virus infection in non-
Hodgkin's lymphoma. Clin Lab Haematol. 1998;20:107-110. 
52. Mazzaro, C., Tirelli, U. & Pozzato, G. Hepatitis C virus and non-Hodgkin's 
lymphoma 10 years later. Dig Liver Dis. 2005;37:219-226. 
53. El-Sayed, G.M., Mohamed, W.S., Nouh, M.A., Moneer, M.M. & El-Mahallawy, 
H.A. Viral genomes and antigen detection of hepatitis B and C viruses in involved 
lymph nodes of Egyptian non-Hodgkin's lymphoma patients. Egypt J Immunol. 
2006;13:105-114. 
54. Ferreri, A.J., Ernberg, I. & Copie-Bergman, C. Infectious agents and lymphoma 
development: molecular and clinical aspects. J Intern Med. 2009;265:421-438. 
55. Merhi, M., et al. Occupational exposure to pesticides and risk of hematopoietic 
cancers: meta-analysis of case-control studies. Cancer Causes Control. 
2007;18:1209-1226. 
56. Smedby, K.E., Askling, J., Mariette, X. & Baecklund, E. Autoimmune and 
inflammatory disorders and risk of malignant lymphomas--an update. J Intern Med. 
2008;264:514-527. 
57. Smedby, K.E., et al. Autoimmune and chronic inflammatory disorders and risk of 
non-Hodgkin lymphoma by subtype. J Natl Cancer Inst. 2006;98:51-60. 
58. Klein, U. & Dalla-Favera, R. Germinal centres: role in B-cell physiology and 
malignancy. Nat Rev Immunol. 2008;8:22-33. 
59. Krishnan, J., Danon, A.D. & Frizzera, G. Reactive lymphadenopathies and atypical 
lymphoproliferative disorders. Am J Clin Pathol. 1993;99:385-396. 
60. Shaffer, A.L., Rosenwald, A. & Staudt, L.M. Lymphoid malignancies: the dark side 
of B-cell differentiation. Nat Rev Immunol. 2002;2:920-932. 
61. Thorbecke, G.J., Amin, A.R. & Tsiagbe, V.K. Biology of germinal centers in 
lymphoid tissue. FASEB J. 1994;8:832-840. 
  54
62. Jones, D. Dismantling the germinal center: comparing the processes of 
transformation, regression, and fragmentation of the lymphoid follicle. Advances in 
anatomic pathology. 2002;9:129-138. 
63. Bachmann, M.F., Odermatt, B., Hengartner, H. & Zinkernagel, R.M. Induction of 
long-lived germinal centers associated with persisting antigen after viral infection. J 
Exp Med. 1996;183:2259-2269. 
64. MacLennan, I.C. Germinal centers. Annu Rev Immunol. 1994;12:117-139. 
65. Hollowood, K. & Goodlad, J.R. Germinal centre cell kinetics. J Pathol. 
1998;185:229-233. 
66. Ellwein, L.B. & Purtilo, D.T. Cellular proliferation and genetic events involved in 
the genesis of Burkitt lymphoma (BL) in immune compromised patients. Cancer 
Genet Cytogenet. 1992;64:42-48. 
67. Natkunam, Y. The biology of the germinal center. Hematology Am Soc Hematol 
Educ Program. 2007;2007:210-215. 
68. Kuppers, R., Klein, U., Hansmann, M.L. & Rajewsky, K. Cellular origin of human 
B-cell lymphomas. N Engl J Med. 1999;341:1520-1529. 
69. Bellan, C., et al. Immunoglobulin gene analysis reveals 2 distinct cells of origin for 
EBV-positive and EBV-negative Burkitt lymphomas. Blood. 2005;106:1031-1036. 
70. Tedoldi, S., et al. Jaw1/LRMP, a germinal centre-associated marker for the 
immunohistological study of B-cell lymphomas. J Pathol. 2006;209:454-463. 
71. Natkunam, Y., et al. Expression of the human germinal center-associated lymphoma 
(HGAL) protein, a new marker of germinal center B-cell derivation. Blood. 
2005;105:3979-3986. 
72. Montes-Moreno, S., et al. Gcet1 (centerin), a highly restricted marker for a subset of 
germinal center-derived lymphomas. Blood. 2008;111:351-358. 
73. Tomita, N., et al. Atypical Burkitt lymphoma arising from follicular lymphoma: 
demonstration by polymerase chain reaction following laser capture microdissection 
and by fluorescence in situ hybridization on paraffin-embedded tissue sections. Am J 
Surg Pathol. 2005;29:121-124. 
74. Mukhopadhyay, S., Readling, J., Cotter, P.D., Shrimpton, A.E. & Sidhu, J.S. 
Transformation of follicular lymphoma to Burkitt-like lymphoma within a single 
lymph node. Hum Pathol. 2005;36:571-575. 
75. Kojima, M., et al. EBV(+) B-cell Lymphoproliferative Disorder Associated with 
Subsequent Development of Burkitt Lymphoma in a Patient with Idiopathic CD4(+) 
T-lymphocytopenia. J Clin Exp Hematop. 2008;48:55-59. 
76. McDonnell, T.J. & Korsmeyer, S.J. Progression from lymphoid hyperplasia to high-
grade malignant lymphoma in mice transgenic for the t(14; 18). Nature. 
1991;349:254-256. 
77. Williams, M.E., et al. Immunoglobulin gene rearrangement in abnormal lymph node 
hyperplasia. Am J Clin Pathol. 1991;96:746-754. 
78. Shibata, D., Weiss, L.M., Nathwani, B.N., Brynes, R.K. & Levine, A.M. Epstein-
Barr virus in benign lymph node biopsies from individuals infected with the human 
immunodeficiency virus is associated with concurrent or subsequent development of 
non-Hodgkin's lymphoma. Blood. 1991;77:1527-1533. 
79. Oviatt, D.L., Cousar, J.B., Collins, R.D., Flexner, J.M. & Stein, R.S. Malignant 
lymphomas of follicular center cell origin in humans. V. Incidence, clinical features, 
and prognostic implications of transformation of small cleaved cell nodular 
lymphoma. Cancer. 1984;53:1109-1114. 
80. Kutok, J.L. & Wang, F. Spectrum of Epstein-Barr virus-associated diseases. Annual 
review of pathology. 2006;1:375-404. 
  55
81. Barozzi, P., et al. B cells and herpesviruses: a model of lymphoproliferation. 
Autoimmun Rev. 2007;7:132-136. 
82. Thorley-Lawson, D.A. & Babcock, G.J. A model for persistent infection with 
Epstein-Barr virus: the stealth virus of human B cells. Life Sci. 1999;65:1433-1453. 
83. Ost, A., et al. Lymphadenopathy in HIV infection: histological classification and 
staging. Apmis. 1989;8:7-15. 
84. Paiva, D.D., et al. Spectrum of morphologic changes of lymph nodes in HIV 
infection. Mem Inst Oswaldo Cruz. 1996;91:371-379. 
85. O'Hara, C.J., Groopman, J.E. & Federman, M. The ultrastructural and 
immunohistochemical demonstration of viral particles in lymph nodes from human 
immunodeficiency virus-related and non-human immunodeficiency virus-related 
lymphadenopathy syndromes. Hum Pathol. 1988;19:545-549. 
86. Burkitt, D., P. Burkitt`s Lymphoma, (E & S Livingstone, Edinburgh & London, 
1970). 
87. Coakley, D. Denis Burkitt and his contribution to haematology/oncology. Br J 
Haematol. 2006;135:17-25. 
88. Shapira, J. & Peylan-Ramu, N. Burkitt's lymphoma. Oral Oncol. 1998;34:15-23. 
89. Ferry, J.A. Burkitt's lymphoma: clinicopathologic features and differential diagnosis. 
Oncologist. 2006;11:375-383. 
90. Harris, N.L., et al. A revised European-American classification of lymphoid 
neoplasms: a proposal from the International Lymphoma Study Group. Blood. 
1994;84:1361-1392. 
91. Wright, D.H. What is Burkitt's lymphoma? J Pathol. 1997;182:125-127. 
92. Wright, D.H. What is Burkitt's lymphoma and when is it endemic? Blood. 
1999;93:758. 
93. Parkin, D.M., et al. Non-Hodgkin lymphoma in Uganda: a case-control study. Aids. 
2000;14:2929-2936. 
94. Palmer. P.E.S., R.M.M. The Imaging of Tropical Diseases.  (Springer, 2000). 
95. IARC Monographs on the Evaluation of Carcinigenic Risk to Humans.Epstein-Barr 
virus and Kaposi`s Sarcoma Herpesvirus/Human Herpesvirus 8., (IARC, Lyon, 
1997). 
96. van den Bosch, C.A. Is endemic Burkitt's lymphoma an alliance between three 
infections and a tumour promoter? Lancet Oncol. 2004;5:738-746. 
97. van den Bosch, C. & Lloyd, G. Chikungunya fever as a risk factor for endemic 
Burkitt's lymphoma in Malawi. Trans R Soc Trop Med Hyg. 2000;94:704-705. 
98. Orem, J., Mbidde, E.K., Lambert, B., de Sanjose, S. & Weiderpass, E. Burkitt's 
lymphoma in Africa, a review of the epidemiology and etiology. Afr Health Sci. 
2007;7:166-175. 
99. Brady, G., MacArthur, G.J. & Farrell, P.J. Epstein-Barr virus and Burkitt lymphoma. 
J Clin Pathol. 2007;60:1397-1402. 
100. Wright, D.H. Lymphoreticular Neoplasms. in Tumors in a Tropical Country: a 
Survey of Uganda 1964-1968 (ed. TEMPLETON, A.C.) 271-297 (Springer-Verlag, 
New York, 1973). 
101. Ogwang, M.D., Bhatia, K., Biggar, R.J. & Mbulaiteye, S.M. Incidence and 
geographic distribution of endemic Burkitt lymphoma in northern Uganda revisited. 
Int J Cancer. 2008. 
102. Gasparini, M., et al. Curability of advanced Burkitt's lymphoma in children by 
intensive short-term chemotherapy. Eur J Cancer. 1993;29A:692-698. 
  56
103. Countouriotis, A., Moore, T.B. & Sakamoto, K.M. Cell surface antigen and 
molecular targeting in the treatment of hematologic malignancies. Stem Cells. 
2002;20:215-229. 
104. Hainsworth, J.D. Monoclonal antibody therapy in lymphoid malignancies. 
Oncologist. 2000;5:376-384. 
105. Foran, J.M. Antibody-based therapy of non-Hodgkin's lymphoma. Best Pract Res 
Clin Haematol. 2002;15:449-465. 
106. Patte, C., et al. Therapy of Burkitt and other B-cell acute lymphoblastic leukaemia 
and lymphoma: experience with the LMB protocols of the SFOP (French Paediatric 
Oncology Society) in children and adults. Baillieres Clin Haematol. 1994;7:339-348. 
107. Yustein, J.T. & Dang, C.V. Biology and treatment of Burkitt's lymphoma. Curr Opin 
Hematol. 2007;14:375-381. 
108. Ribeiro, R.C. & Sandlund, J.T. Burkitt lymphoma in African children: a priority for 
the global health agenda? Pediatr Blood Cancer. 2008;50:1125-1126. 
109. Hesseling, P.B., et al. Malawi pilot study of Burkitt lymphoma treatment. Med 
Pediatr Oncol. 2003;41:532-540. 
110. Orem, J., Maganda, A., Mbidde, E.K. & Weiderpass, E. Clinical characteristics and 
outcome of children with Burkitt lymphoma in Uganda according to HIV infection. 
Pediatr Blood Cancer. 2008. 
111. Kearns, D.B., Smith, R.J. & Pitcock, J.K. Burkitt's lymphoma. Int J Pediatr 
Otorhinolaryngol. 1986;12:73-84. 
112. Fujita, S., et al. Early stage of Epstein-Barr virus lytic infection leading to the "starry 
sky" pattern formation in endemic Burkitt lymphoma. Arch Pathol Lab Med. 
2004;128:549-552. 
113. Hui, P.K., Feller, A.C. & Lennert, K. High-grade non-Hodgkin's lymphoma of B-cell 
type. I. Histopathology. Histopathology. 1988;12:127-143. 
114. Orem, J., Mbidde, E.K. & Weiderpass, E. Current investigations and treatment of 
Burkitt's lymphoma in Africa. Trop Doct. 2008;38:7-11. 
115. Spina, D., et al. Cellular kinetic and phenotypic heterogeneity in and among Burkitt's 
and Burkitt-like lymphomas. J Pathol. 1997;182:145-150. 
116. Barth, T.F., et al. Homogeneous immunophenotype and paucity of secondary 
genomic aberrations are distinctive features of endemic but not of sporadic Burkitt's 
lymphoma and diffuse large B-cell lymphoma with MYC rearrangement. J Pathol. 
2004;203:940-945. 
117. Pecorino.Lauren (ed.) MOLECULAR BIOLGY OF CANCER. Mechanisms, Targets, 
and Therapeutics, (Oxford University Press, Oxford, 2005). 
118. Hanahan, D. & Weinberg, R.A. The hallmarks of cancer. Cell. 2000;100:57-70. 
119. Vogelstein, B. & Kinzler, K.W. Cancer genes and the pathways they control. Nat 
Med. 2004;10:789-799. 
120. Lindstrom, M.S. & Wiman, K.G. Role of genetic and epigenetic changes in Burkitt 
lymphoma. Semin Cancer Biol. 2002;12:381-387. 
121. Bellan, C., et al. Burkitt's lymphoma: new insights into molecular pathogenesis. J 
Clin Pathol. 2003;56:188-192. 
122. de Alboran, I.M., Robles, M.S., Bras, A., Baena, E. & Martinez, A.C. Cell death 
during lymphocyte development and activation. Semin Immunol. 2003;15:125-133. 
123. Sanchez-Beato, M., Sanchez-Aguilera, A. & Piris, M.A. Cell cycle deregulation in 
B-cell lymphomas. Blood. 2003;101:1220-1235. 
124. Blagosklonny, M.V. & Pardee, A.B. The restriction point of the cell cycle. Cell 
Cycle. 2002;1:103-110. 
  57
125. Hecht, J.L. & Aster, J.C. Molecular biology of Burkitt's lymphoma. J Clin Oncol. 
2000;18:3707-3721. 
126. Pucci, B., Kasten, M. & Giordano, A. Cell cycle and apoptosis. Neoplasia. 
2000;2:291-299. 
127. Giono, L.E. & Manfredi, J.J. The p53 tumor suppressor participates in multiple cell 
cycle checkpoints. J Cell Physiol. 2006;209:13-20. 
128. Vogelstein, B., Lane, D. & Levine, A.J. Surfing the p53 network. Nature. 
2000;408:307-310. 
129. Garriga, J., et al. Differential regulation of the retinoblastoma family of proteins 
during cell proliferation and differentiation. Biochem J. 1998;333 ( Pt 3):645-654. 
130. Claudio, P.P., et al. p130/pRb2 has growth suppressive properties similar to yet 
distinctive from those of retinoblastoma family members pRb and p107. Cancer 
research. 1994;54:5556-5560. 
131. Howard, C.M., et al. Retinoblastoma-related protein pRb2/p130 and suppression of 
tumor growth in vivo. J Natl Cancer Inst. 1998;90:1451-1460. 
132. Pupa, S.M., et al. Ectopic expression of pRb2/p130 suppresses the tumorigenicity of 
the c-erbB-2-overexpressing SKOV3 tumor cell line. Oncogene. 1999;18:651-656. 
133. Leoncini, L., et al. Retinoblastoma-related p107 and pRb2/p130 proteins in 
malignant lymphomas: distinct mechanisms of cell growth control. Clin Cancer Res. 
1999;5:4065-4072. 
134. Gillett, C.E. & Barnes, D.M. Demystified ... cell cycle. Mol Pathol. 1998;51:310-
316. 
135. Sherr, C.J. The Pezcoller lecture: cancer cell cycles revisited. Cancer research. 
2000;60:3689-3695. 
136. Slingerland, J. & Pagano, M. Regulation of the cdk inhibitor p27 and its deregulation 
in cancer. J Cell Physiol. 2000;183:10-17. 
137. Hartwell, L.H. & Kastan, M.B. Cell cycle control and cancer. Science. 
1994;266:1821-1828. 
138. Strauss, M., Lukas, J. & Bartek, J. Unrestricted cell cycling and cancer. Nat Med. 
1995;1:1245-1246. 
139. Sherr, C.J. Cancer cell cycles. Science. 1996;274:1672-1677. 
140. Debatin, K.M., Stahnke, K. & Fulda, S. Apoptosis in hematological disorders. Semin 
Cancer Biol. 2003;13:149-158. 
141. Mullauer, L., et al. Mutations in apoptosis genes: a pathogenetic factor for human 
disease. Mutat Res. 2001;488:211-231. 
142. Staunton, M.J. & Gaffney, E.F. Apoptosis: basic concepts and potential significance 
in human cancer. Arch Pathol Lab Med. 1998;122:310-319. 
143. Martinez-Valdez, H., et al. Human germinal center B cells express the apoptosis-
inducing genes Fas, c-myc, P53, and Bax but not the survival gene bcl-2. J Exp Med. 
1996;183:971-977. 
144. Krajewski, S., et al. Immunohistochemical analysis of Mcl-1 and Bcl-2 proteins in 
normal and neoplastic lymph nodes. Am J Pathol. 1994;145:515-525. 
145. Akyurek, N., Ren, Y., Rassidakis, G.Z., Schlette, E.J. & Medeiros, L.J. Expression of 
inhibitor of apoptosis proteins in B-cell non-Hodgkin and Hodgkin lymphomas. 
Cancer. 2006;107:1844-1851. 
146. Werner, M., Chott, A., Fabiano, A. & Battifora, H. Effect of formalin tissue fixation 
and processing on immunohistochemistry. Am J Surg Pathol. 2000;24:1016-1019. 
147. Greer, C.E., Wheeler, C.M. & Manos, M.M. Sample preparation and PCR 
amplification from paraffin-embedded tissues. PCR Methods Appl. 1994;3:S113-
122. 
  58
148. Gown, A.M. Unmasking the mysteries of antigen or epitope retrieval and formalin 
fixation. Am J Clin Pathol. 2004;121:172-174. 
149. Shi, S.R., et al. DNA extraction from archival formalin-fixed, paraffin-embedded 
tissues: heat-induced retrieval in alkaline solution. Histochem Cell Biol. 
2004;122:211-218. 
150. Valsecchi, M.G. & Steliarova-Foucher, E. Cancer registration in developing 
countries: luxury or necessity? Lancet Oncol. 2008;9:159-167. 
151. Stiller, C.A. Reliability of cancer registration data. Eur J Cancer. 1997;33:812-814. 
152. Brewster, D. Improving the quality of cancer registration data. J R Soc Med. 
1995;88:268-271. 
153. Parkin, D.M., Wabinga, H. & Nambooze, S. Completeness in an African cancer 
registry. Cancer Causes Control. 2001;12:147-152. 
154. Zettl, A., et al. Immunohistochemical analysis of B-cell lymphoma using tissue 
microarrays identifies particular phenotypic profiles of B-cell lymphomas. 
Histopathology. 2003;43:209-219. 
155. Tzankov, A., Went, P., Zimpfer, A. & Dirnhofer, S. Tissue microarray technology: 
principles, pitfalls and perspectives--lessons learned from hematological 
malignancies. Exp Gerontol. 2005;40:737-744. 
156. Bubendorf, L., Nocito, A., Moch, H. & Sauter, G. Tissue microarray (TMA) 
technology: miniaturized pathology archives for high-throughput in situ studies. J 
Pathol. 2001;195:72-79. 
157. Kalebi, A.Y. & Dada, M.A. Application of immunohistochemistry in clinical 
practice: a review. East Afr Med J. 2007;84:389-397. 
158. Montero, C. The antigen-antibody reaction in immunohistochemistry. J Histochem 
Cytochem. 2003;51:1-4. 
159. MacIntyre, N. Unmasking antigens for immunohistochemistry. Br J Biomed Sci. 
2001;58:190-196. 
160. Shi, S.R., Cote, R.J. & Taylor, C.R. Antigen retrieval techniques: current 
perspectives. J Histochem Cytochem. 2001;49:931-937. 
161. Shi, S.R., et al. Development of an optimal protocol for antigen retrieval: a 'test 
battery' approach exemplified with reference to the staining of retinoblastoma protein 
(pRB) in formalin-fixed paraffin sections. J Pathol. 1996;179:347-352. 
162. Immunohistochemical Staining Methods, (Dako, Carpinteria,California, 2006). 
163. Sabattini, E., et al. The EnVision++ system: a new immunohistochemical method for 
diagnostics and research. Critical comparison with the APAAP, ChemMate, CSA, 
LABC, and SABC techniques. J Clin Pathol. 1998;51:506-511. 
164. Zhang, H., et al. Localization of enteroviral antigen in myocardium and other tissues 
from patients with heart muscle disease by an improved immunohistochemical 
technique. J Histochem Cytochem. 2000;48:579-584. 
165. Kammerer, U., et al. A new rapid immunohistochemical staining technique using the 
EnVision antibody complex. J Histochem Cytochem. 2001;49:623-630. 
166. Hutchison, R.E., et al. Burkitt lymphoma is immunophenotypically different from 
Burkitt-like lymphoma in young persons. Ann Oncol. 2000;11 Suppl 1:35-38. 
167. Nakamura, N., et al. The distinction between Burkitt lymphoma and diffuse large B-
Cell lymphoma with c-myc rearrangement. Mod Pathol. 2002;15:771-776. 
168. Frost, M., et al. Comparative immunohistochemical analysis of pediatric Burkitt 
lymphoma and diffuse large B-cell lymphoma. Am J Clin Pathol. 2004;121:384-392. 
169. Chang, C.C., et al. Immunohistochemical expression patterns of germinal center and 
activation B-cell markers correlate with prognosis in diffuse large B-cell lymphoma. 
Am J Surg Pathol. 2004;28:464-470. 
  59
170. Zinzani, P.L., et al. Identification of outcome predictors in diffuse large B-cell 
lymphoma. Immunohistochemical profiling of homogeneously treated de novo 
tumors with nodal presentation on tissue micro-arrays. Haematologica. 2005;90:341-
347. 
171. Bossuyt, P.M., et al. Towards complete and accurate reporting of studies of 
diagnostic accuracy: the STARD initiative. Standards for Reporting of Diagnostic 
Accuracy. Clin Chem. 2003;49:1-6. 
172. McShane, L.M., et al. Reporting recommendations for tumor marker prognostic 
studies (REMARK). J Natl Cancer Inst. 2005;97:1180-1184. 
173. Mies, C. Molecular biological analysis of paraffin-embedded tissues. Hum Pathol. 
1994;25:555-560. 
174. Leich, E., Hartmann, E.M., Burek, C., Ott, G. & Rosenwald, A. Diagnostic and 
prognostic significance of gene expression profiling in lymphomas. Apmis. 
2007;115:1135-1146. 
175. Ferreira, B.I., et al. Comparative genome profiling across subtypes of low-grade B-
cell lymphoma identifies type-specific and common aberrations that target genes 
with a role in B-cell neoplasia. Haematologica. 2008;93:670-679. 
176. Piccaluga, P.P., et al. Gene expression analysis provides a potential rationale for 
revising the histological grading of follicular lymphomas. Haematologica. 
2008;93:1033-1038. 
177. Rosenwald, A., et al. The use of molecular profiling to predict survival after 
chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:1937-
1947. 
178. Lenz, G., et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med. 
2008;359:2313-2323. 
179. Shibata, D. Extraction of DNA from paraffin-embedded tissue for analysis by 
polymerase chain reaction: new tricks from an old friend. Hum Pathol. 1994;25:561-
563. 
180. Sato, Y., et al. Comparison of the DNA extraction methods for polymerase chain 
reaction amplification from formalin-fixed and paraffin-embedded tissues. Diagn 
Mol Pathol. 2001;10:265-271. 
181. Campidelli, C., Gazzola, A., Vitone, F., Pileri, S.A. & Tumwine, L. HIV infection 
and c-MYC status in endemic Burkitt lymphoma. Hum Pathol. 2008;39:1408-1409. 
182. Akslen, L.A., et al. Mutation analysis of the EGFR-NRAS-BRAF pathway in 
melanomas from black Africans and other subgroups of cutaneous melanoma. 
Melanoma Res. 2008;18:29-35. 
183. Omoti, C.E. & Halim, N.K. Adult lymphomas in Edo state, Niger Delta region of 
Nigeria--clinicopathological profile of 205 cases. Clin Lab Haematol. 2005;27:302-
306. 
184. Macartney, J.C., Rollason, T.P. & Codling, B.W. Use of a histopathology data pool 
for epidemiological analysis. J Clin Pathol. 1980;33:351-355. 
185. Parkin, D.M., et al. Part I: Cancer in Indigenous Africans--burden, distribution, and 
trends. Lancet Oncol. 2008;9:683-692. 
186. Harris, N.L., et al. Lymphoma classification--from controversy to consensus: the 
R.E.A.L. and WHO Classification of lymphoid neoplasms. Ann Oncol. 2000;11 
Suppl 1:3-10. 
187. Jaffe, E.S., Raffeld, M., Medeiros, L.J. & Stetler-Stevenson, M. An overview of the 
classification of non-Hodgkin's lymphomas: an integration of morphological and 
phenotypical concepts. Cancer research. 1992;52:5447s-5452s. 
  60
188. Patel, A.A., et al. Availability and quality of paraffin blocks identified in pathology 
archives: a multi-institutional study by the Shared Pathology Informatics Network 
(SPIN). BMC Cancer. 2007;7:37. 
189. Nocito, A., Kononen, J., Kallioniemi, O.P. & Sauter, G. Tissue microarrays (TMAs) 
for high-throughput molecular pathology research. Int J Cancer. 2001;94:1-5. 
190. Lehmann, U. & Kreipe, H. Real-time PCR analysis of DNA and RNA extracted from 
formalin-fixed and paraffin-embedded biopsies. Methods. 2001;25:409-418. 
191. Wu, L., Patten, N., Yamashiro, C.T. & Chui, B. Extraction and amplification of DNA 
from formalin-fixed, paraffin-embedded tissues. Appl Immunohistochem Mol 
Morphol. 2002;10:269-274. 
192. Okello, J.B., et al. Comparison of methods in the recovery of nucleic acids from 
archival formalin-fixed paraffin-embedded autopsy tissues. Anal Biochem.400:110-
117. 
193. Parkin, D.M., Bray, F., Ferlay, J. & Pisani, P. Global cancer statistics, 2002. CA 
Cancer J Clin. 2005;55:74-108. 
194. Sitas, F., et al. Part II: Cancer in Indigenous Africans--causes and control. Lancet 
Oncol. 2008;9:786-795. 
195. Cote, T.R., et al. Non-Hodgkin's lymphoma among people with AIDS: incidence, 
presentation and public health burden. AIDS/Cancer Study Group. Int J Cancer. 
1997;73:645-650. 
196. Gray, I.P. & Carter, J.Y. An evaluation of clinical laboratory services in sub-Saharan 
Africa. Ex africa semper aliquid novi? Clinica chimica acta; international journal of 
clinical chemistry. 1997;267:103-128. 
197. UNAIDS. Stepping back from the edge : the pursuit of antiretroviral therapy in 
Botswana, South Africa and Uganda.  42-58 (Geneva, 2004). 
198. HIV and AIDS in Uganda.  [cited 30th November 2010]; Available from: 
http://www.avert.org/aids-uganda.htm. 
199. Habermann, T.M. & Steensma, D.P. Lymphadenopathy. Mayo Clinic proceedings. 
2000;75:723-732. 
200. Brown, J.R. & Skarin, A.T. Clinical mimics of lymphoma. Oncologist. 2004;9:406-
416. 
201. Bakaki, P., et al. Epidemiologic and clinical features of HIV-infected and HIV-
uninfected Ugandan children younger than 18 months. Journal of acquired immune 
deficiency syndromes (1999). 2001;28:35-42. 
202. Ioachim, H.L. & Ratech, H. Ioachim`s Lymph node Pathology, (Lippincott Williams 
& Wilkins, Philadelphia, 2002). 
203. Moore, S.W., Schneider, J.W. & Schaaf, H.S. Diagnostic aspects of cervical 
lymphadenopathy in children in the developing world: a study of 1,877 surgical 
specimens. Pediatric surgery international. 2003;19:240-244. 
204. Sibanda, E.N. & Stanczuk, G. Lymph node pathology in Zimbabwe: a review of 
2194 specimens. The Quarterly journal of medicine. 1993;86:811-817. 
205. Chau, I., et al. Rapid access multidisciplinary lymph node diagnostic clinic: analysis 
of 550 patients. Br J Cancer. 2003;88:354-361. 
206. Yaris, N., Cakir, M., Sozen, E. & Cobanoglu, U. Analysis of children with peripheral 
lymphadenopathy. Clinical pediatrics. 2006;45:544-549. 
207. Mbulaiteye, S.M., et al. High levels of Epstein-Barr virus DNA in saliva and 
peripheral blood from Ugandan mother-child pairs. The Journal of infectious 
diseases. 2006;193:422-426. 
208. Crawford, D.H. Biology and disease associations of Epstein-Barr virus. Philos Trans 
R Soc Lond B Biol Sci. 2001;356:461-473. 
  61
209. Petti, C.A., Polage, C.R., Quinn, T.C., Ronald, A.R. & Sande, M.A. Laboratory 
medicine in Africa: a barrier to effective health care. Clin Infect Dis. 2006;42:377-
382. 
210. Brousset, P., et al. Characterization of Epstein-Barr virus-infected cells in benign 
lymphadenopathy of patients seropositive for human immunodeficiency virus. Hum 
Pathol. 1996;27:263-268. 
211. Cinti, C., et al. Genetic alterations of the retinoblastoma-related gene RB2/p130 
identify different pathogenetic mechanisms in and among Burkitt's lymphoma 
subtypes. Am J Pathol. 2000;156:751-760. 
212. Klumb, C.E., et al. Retinoblastoma-related geneRb2/p130 are rarely mutated in 
Burkitt's lymphoma from Brazil. American journal of hematology. 2007;82:238-239. 
213. Zamparelli, A., et al. Expression of cell-cycle-associated proteins pRB2/p130 and 
p27kip in vulvar squamous cell carcinomas. Hum Pathol. 2001;32:4-9. 
214. Li, Q., et al. Expression of Rb2/p130 protein correlates with the degree of 
malignancy in gliomas. Brain Tumor Pathol. 2004;21:121-125. 
215. D'Andrilli, G., et al. Frequent loss of pRb2/p130 in human ovarian carcinoma. Clin 
Cancer Res. 2004;10:3098-3103. 
216. Chestukhin, A., Litovchick, L., Rudich, K. & DeCaprio, J.A. Nucleocytoplasmic 
shuttling of p130/RBL2: novel regulatory mechanism. Mol Cell Biol. 2002;22:453-
468. 
217. Lazzi, S., et al. Expression of RB2/p130 tumor-suppressor gene in AIDS-related 
non-Hodgkin's lymphomas: implications for disease pathogenesis. Hum Pathol. 
2002;33:723-731. 
218. Stewart, C.L., Soria, A.M. & Hamel, P.A. Integration of the pRB and p53 cell cycle 
control pathways. J Neurooncol. 2001;51:183-204. 
219. Bai, M., et al. Low expression of p27 protein combined with altered p53 and Rb/p16 
expression status is associated with increased expression of cyclin A and cyclin B1 in 
diffuse large B-cell lymphomas. Mod Pathol. 2001;14:1105-1113. 
220. Paik, J.H., et al. Expression and prognostic implications of cell cycle regulatory 
molecules, p16, p21, p27, p14 and p53 in germinal centre and non-germinal centre B-
like diffuse large B-cell lymphomas. Histopathology. 2005;47:281-291. 
221. Sanchez-Beato, M., et al. Overall survival in aggressive B-cell lymphomas is 
dependent on the accumulation of alterations in p53, p16, and p27. Am J Pathol. 
2001;159:205-213. 
222. Kramer, A., et al. Alterations of the cyclin D1/pRb/p16(INK4A) pathway in multiple 
myeloma. Leukemia. 2002;16:1844-1851. 
223. Zolota, V., Sirinian, C., Melachrinou, M., Symeonidis, A. & Bonikos, D.S. 
Expression of the regulatory cell cycle proteins p21, p27, p14, p16, p53, mdm2, and 
cyclin E in bone marrow biopsies with acute myeloid leukemia. Correlation with 
patients' survival. Pathol Res Pract. 2007;203:199-207. 
224. Mansukhani, M.M., Osborne, B.M., Zhong, J. & Matsushima, A.Y. The pattern of 
p53 and p21WAF1/CIP1 immunoreactivity in non-Hodgkin's lymphomas predicts 
p53 gene status. Diagn Mol Pathol. 1997;6:222-228. 
225. Klumb, C.E., et al. p53 gene analysis in childhood B non-Hodgkin's lymphoma. Sao 
Paulo medical journal = Revista paulista de medicina. 2001;119:212-215. 
226. Bornkamm, G.W. Epstein-Barr virus and the pathogenesis of Burkitt's lymphoma: 
more questions than answers. Int J Cancer. 2009;124:1745-1755. 
227. Hummel, M., et al. A biologic definition of Burkitt's lymphoma from transcriptional 
and genomic profiling. N Engl J Med. 2006;354:2419-2430. 
 
